var title_f15_35_15920="12-lead ECG right lateral WPW";
var content_f15_35_15920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a right lateral accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Electrocardiogram in sinus rhythm from a patient with Wolff-Parkinson-White syndrome shows classic preexcitation with a short PR interval, delta wave, and widened QRS complex with a left bundle branch block morphology. The delta wave is positive in the lateral leads 1, aVL, and V6, it is negative in lead III and isoelectric in lead aVF. The QRS axis of &lt;30L distinguishes this pathway from an anteroseptal accessory AV pathway.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15920=[""].join("\n");
var outline_f15_35_15920=null;
var title_f15_35_15921="Protein in the urine (proteinuria)";
var content_f15_35_15921=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/35/15921/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15921/contributors\" id=\"au8355\">",
"       Brad H Rovin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/35/15921/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15921/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/35/15921/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15921/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/35/15921?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The kidneys job is to remove wastes and excess water and salts from the blood. Kidneys receive blood through the renal arteries (",
"     <a class=\"graphic graphic_figure graphicRef80336 \" href=\"UTD.htm?3/35/3634\">",
"      figure 1",
"     </a>",
"     ). The blood flows into parts of the kidney called nephrons (",
"     <a class=\"graphic graphic_figure graphicRef82497 \" href=\"UTD.htm?5/10/5286\">",
"      figure 2",
"     </a>",
"     ). Each nephron is made of a glomerulus and a tubule. Each kidney contains hundreds of thousands of nephrons.",
"    </p>",
"    <p>",
"     The glomeruli filter the blood, removing waste products from the blood. They also prevent some substances, such as protein, from being taken out of the blood. If the glomeruli are damaged, protein from the blood leaks into the urine.",
"    </p>",
"    <p>",
"     Normally, you should have less than 150 milligrams (about 3 percent of a teaspoon) of protein in the urine per day. Having more than 150 milligrams per day is called proteinuria.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DOES PROTEINURIA CAUSE SYMPTOMS?",
"     </span>",
"    </p>",
"    <p>",
"     People with a small amount of proteinuria generally have no signs or symptoms. However, some patients have edema (swelling) in the face, legs, or both if they lose large amounts of protein in their urine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TYPES OF PROTEINURIA",
"     </span>",
"    </p>",
"    <p>",
"     Proteinuria can be divided into three categories: transient (intermittent), orthostatic (related to",
"     <span class=\"nowrap\">",
"      sitting/standing",
"     </span>",
"     or lying down), and persistent (always present).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Transient proteinuria",
"     </span>",
"     &nbsp;&mdash;&nbsp;Transient (intermittent) proteinuria is by far the most common form of proteinuria. Transient proteinuria usually resolves without treatment. Stresses such as fever and exercise may cause transient proteinuria.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Orthostatic proteinuria",
"     </span>",
"     &nbsp;&mdash;&nbsp;Orthostatic proteinuria occurs when one loses protein in the urine while in an upright position but not when lying down. It occurs in 2 to 5 percent of adolescents but is unusual in people over the age of 30 years. The cause of orthostatic proteinuria is not known. Orthostatic proteinuria is not harmful, does not require treatment, and typically disappears with age.",
"    </p>",
"    <p>",
"     Orthostatic proteinuria is diagnosed by obtaining a split urine collection. This requires collecting two urine samples: one while you are standing or sitting up (usually during the day) and another after you have been sleeping for several hours (eg, first thing in the morning) (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Urine testing'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Persistent proteinuria",
"     </span>",
"     &nbsp;&mdash;&nbsp;In contrast to transient and orthostatic proteinuria, persistent proteinuria occurs in people with underlying kidney disease or other medical problems. Examples include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart or blood vessel disease",
"      </li>",
"      <li>",
"       A disease in the body that produces abnormal proteins",
"      </li>",
"      <li>",
"       A disorder that affects how the kidneys work (eg, kidney disease)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PROTEINURIA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Urine testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Proteinuria is diagnosed by analyzing the urine (called a urinalysis), often with a dipstick test. However, dipstick testing is not very precise. Also, people should have the urine test repeated. It is not uncommon to have proteinuria temporarily, and repeat urine tests are usually normal.",
"    </p>",
"    <p>",
"     The urine should also be examined with a microscope to see if there are cells, crystals, bacteria, or structures called casts. These urine elements can be signs of specific types of kidney problems (for example, diseases that injury the glomeruli). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"      \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If two or more urinalyses show protein in the urine, the next step is to determine how much protein is in the urine. This can be measured from:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A single urine sample collected at any time (a common and convenient method).",
"      </li>",
"      <li>",
"       Urine that has been collected over 24 hours (a more exact but somewhat inconvenient method). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"        \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If your doctor or nurse asks you to collect urine at home, try to keep it in a cool place, like the refrigerator.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Blood testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your doctor or nurse might also ask you to have blood tests to see how well your kidneys are working (called kidney function testing). These include measurement of BUN (blood urea nitrogen) and creatinine and then calculating how well the kidneys work with a formula to determine the glomerular filtration rate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Kidney biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your doctor might recommend a test called a kidney biopsy. During a biopsy, a doctor takes a small piece of one kidney and then looks at the tissue under the microscope. Many people with proteinuria will not need a kidney biopsy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"      \"Patient information: Renal (kidney) biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      PROTEINURIA TREATMENT AND PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Transient and orthostatic proteinuria are not harmful conditions, and no specific treatment is needed.",
"    </p>",
"    <p>",
"     Patients with persistent low-grade proteinuria that is not related to decreased kidney function or a systemic disease typically have no long-term complications, even if untreated. Many nephrologists use an antihypertensive drug, such as an angiotensin converting enzyme (ACE) inhibitor, to reduce or eliminate proteinuria.",
"    </p>",
"    <p>",
"     In patients with persistent high-grade proteinuria who have decreased kidney function, the underlying condition is usually treated. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Normally, protein should not be found in the urine. A person who has protein in the urine is said to have proteinuria",
"      </li>",
"      <li>",
"       Most people have no signs or symptoms of proteinuria",
"      </li>",
"      <li>",
"       Proteinuria is usually discovered with a urine dipstick test that is done for another reason",
"      </li>",
"      <li>",
"       There are three types of proteinuria: transient (temporary), orthostatic (related to",
"       <span class=\"nowrap\">",
"        sitting/standing",
"       </span>",
"       or lying down), and persistent (always present)",
"      </li>",
"      <li>",
"       Several urine tests are needed to determine which type of proteinuria a person has. Some people also need blood tests or an exam by a doctor or nurse",
"      </li>",
"      <li>",
"       Transient and orthostatic proteinuria do not cause long-lasting health problems and do not usually need to be treated",
"      </li>",
"      <li>",
"       Some people with persistent proteinuria have kidney problems that need to be treated",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287264617\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292593867\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/62/9188?source=see_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292593875\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=see_link\">",
"      Evaluation of proteinuria in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=see_link\">",
"      Orthostatic (postural) proteinuria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Kidney Fund",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidneyfund.org/\">",
"      www.kidneyfund.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association of Kidney Patients",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aakp.org/\">",
"      www.aakp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/35/15921/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"    <p>",
"     <strong>",
"      ACKNOWLEDGMENT",
"     </strong>",
"     &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Suzanne Fletcher, MD, who contributed to an earlier version of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/35/15921?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15921/abstract/1\">",
"      Robinson RR. Isolated proteinuria in asymptomatic patients. Kidney Int 1980; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15921/abstract/2\">",
"      Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 2000; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15921/abstract/3\">",
"      Springberg PD, Garrett LE Jr, Thompson AL Jr, et al. Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med 1982; 97:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15921/abstract/4\">",
"      Rytand DA, Spreiter S. Prognosis in postural (orthostatic) proteinuria: forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med 1981; 305:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15921/abstract/5\">",
"      Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol 1996; 45:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_35_15921=[""].join("\n");
var outline_f15_35_15921=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DOES PROTEINURIA CAUSE SYMPTOMS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TYPES OF PROTEINURIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PROTEINURIA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           PROTEINURIA TREATMENT AND PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/35/3634\" title=\"figure 1\">",
"           Kidney anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/10/5286\" title=\"figure 2\">",
"           Nephron anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_35_15922="Endemic areas P marneffei";
var content_f15_35_15922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endemic areas of",
"    <em>",
"     Penicillium marneffei",
"    </em>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15922=[""].join("\n");
var outline_f15_35_15922=null;
var title_f15_35_15923="Sinecatechins: Drug information";
var content_f15_35_15923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sinecatechins: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/54/8036?source=see_link\">",
"    see \"Sinecatechins: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5195544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Veregen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5195548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Immunomodulator, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5195575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Condylomata acuminata:",
"     </i>",
"     Topical: Apply a thin layer (~0.5 cm strand) 3 times/day to all external genital and perianal warts until all warts have been cleared (maximum duration: 16 weeks)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5195576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5195577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5195582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veregen&reg;: 15% (15 g, 30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5195546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5195578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands before and after application; apply with fingers, leaving a thin layer of ointment; do not wash ointment off affected area after application. Discontinue treatment if the severity of local skin reactions becomes unacceptable. Do not apply internally; do not apply to open wounds; do not apply occlusive dressing. Sexual contact should be avoided while ointment is on skin. For females requiring tampon use during treatment, tampon should be inserted prior to application of ointment to prevent accidental application of ointment into the vagina. May stain clothing or bedding.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5195550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of external genital and perianal warts secondary to condylomata acuminata",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5195560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Erythema (70%), pruritus (69%), edema (45%), vesicular rash (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Burning (67%), pain/discomfort (56%), erosion/ulceration (49%), induration (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Desquamation (5%), rash (1%), scar formation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Discharge (3%), lymphadenitis (3%), bleeding (2%), reaction (2%), irritation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Phimosis (uncircumcised males; 3%), hypersensitivity (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Discoloration, dryness, eczema, facial rash, hyperesthesia, necrosis, papules, pelvic pain, perianal infection, pigmentation changes, staphylococcemia, urethritis, vulvitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5195555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5195556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin irritation: Local skin reactions are common, if possible, continue treatment; severe reactions may require treatment interruption or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HPV infection: Not intended for the treatment of urethral, intravaginal, cervical, rectal, or intra-anal human papilloma viral disease. Women should continue to undergo regular gynecological examination, including monitoring and screening for cervical dysplasia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunosuppressed patients: Safety and efficacy have not been established in immunosuppressed patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Women: Severe reactions were reported more commonly in women; it is possible that women are at a higher risk of serious local events (eg, erosion/ulceration, burning, itching, pain).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For topical use only; ointment is",
"     <b>",
"      not",
"     </b>",
"     intended for internal use; avoid topical application to open wounds; has been shown to increase the risk of adverse reactions. Avoid exposure of treated area to sun and/or UV-light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Duration of therapy: Continue treatment until all warts have been cleared (maximum duration: 16 weeks); the safety and efficacy of treatment lasting &gt;16 weeks have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5195566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5195551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5195552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use only if possible benefit outweighs potential risk to the fetus. Sinecatechins ointment may weaken condoms and diaphragms.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5195554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Green Tea Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (50): $4.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Veregen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (15 g): $447.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5195580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine gynecological exams (females)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5195569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The mechanism by which sinecatechins ointment aids in the clearance of genital and perianal warts is unknown. Antioxidant properties have been demonstrated",
"     <i>",
"      in vitro",
"     </i>",
"     ; however, the significance of this finding is not known.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5195571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Topical: Not sufficiently studied; based on limited data, minimal systemic absorption is expected.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/35/15923/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9452 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15923=[""].join("\n");
var outline_f15_35_15923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195544\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195548\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195575\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195576\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195577\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195582\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195546\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195578\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195550\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195555\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195556\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300045\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195566\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195551\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195552\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195554\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324145\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195580\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195569\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195571\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/54/8036?source=related_link\">",
"      Sinecatechins: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_35_15924="Tuberculin skin test: Drug information";
var content_f15_35_15924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tuberculin skin test: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/2/15395?source=see_link\">",
"    see \"Tuberculin skin test: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aplisol&reg;;",
"     </li>",
"     <li>",
"      Tubersol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnosis of tuberculosis, cell-mediated immunodeficiencies:",
"     </b>",
"     Intradermal: 0.1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      TST interpretation: Criteria for positive TST read at 48-72 hours (see Note below for healthcare workers):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Induration &ge;5 mm: Persons with HIV infection (or risk factors for HIV infection, but unknown status), recent close contact to person with known active TB, persons with chest x-ray consistent with healed TB, persons who are immunosuppressed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Induration &ge;10 mm: Persons with clinical conditions which increase risk of TB infection, recent immigrants, I.V. drug users, residents and employees of high-risk settings, children &lt;4 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Induration &ge;15 mm: Persons who do not meet any of the above criteria (no risk factors for TB)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A two-step test is recommended when testing will be performed at regular intervals (eg, for healthcare workers). If the first test is negative, a second TST should be administered 1-3 weeks after the first test was read.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      TST interpretation (CDC guidelines) in a healthcare setting:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Baseline test: &ge;10 mm is positive (either first or second step)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serial testing without known exposure: Increase of  &ge;10 mm is positive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Known exposure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     &ge;5 mm is positive in patients with baseline of 0 mm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     &ge;10 mm is positive in patients with negative baseline or previous screening result of &ge;0 mm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Read test at 48-72 hours following placement. Test results with 0 mm induration or measured induration less than the defined cutoff point are considered to signify absence of infection with",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     . Test results should be documented in millimeters even if classified as negative. Erythema and redness of skin are not indicative of a positive test result.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F232329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aplisol&reg;: 5 TU/0.1 mL (1 mL, 5 mL) [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tubersol&reg;: 5 TU/0.1 mL (1 mL, 5 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intradermal administration only. Administer to upper third of forearm (palm up)  &ge;2 inches from elbow, wrist, or other injection site. If neither arm can be used, may administer to back of shoulder. Administer using  inch",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch 27-gauge needle or finer tuberculin syringe. Should form wheal (6-10 mm in diameter) as liquid is injected which will remain ~10 minutes. Avoid pressure or bandage at injection site. Document date and time of injection, person placing TST, location of injection site, and lot number of solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin test in diagnosis of tuberculosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F232338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aplisol&reg; may be confused with Anusol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tuberculin products may be confused with tetanus toxoid products, poliovirus vaccine (inactivated), and influenza virus vaccine. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suspected adverse reactions should be reported to the Food and Drug Administration (FDA) MedWatch Program at 1-800-332-1088",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Bleeding, bruising, discomfort, erythematous reaction, hematoma, necrosis, pain, pruritus, redness, scarring, ulceration, vesiculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tuberculin purified protein derivative (PPD) or any component of the formulation; previous severe reaction to tuberculin PPD skin test (TST)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burns: Do not administer to persons with extensive burns.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eczema: Do not administer to persons with eczema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Do not administer to persons with documented tuberculosis or a clear history of treatment for tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Viral infections: Skin testing may be deferred with major viral infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Very young children (&lt;6 weeks of age) may also have an absent or delayed response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For intradermal administration only; do not administer I.V., I.M., or SubQ. Epinephrine (1:1000) should be available to treat possible allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Patients with a previous severe reaction to TST (vesiculation, ulceration, necrosis) at the injection site should not receive tuberculin PPD again.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions decreasing response: Tuberculous or other bacterial infections, viral infection, live virus vaccination, malignancy, immunosuppressive agents, and conditions which impair immune response may cause a decreased response to test.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccinations: Skin testing may be deferred with live-virus vaccination within 1 month.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): May diminish the diagnostic effect of Tuberculin Tests. Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3466540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Pregnancy is not a contraindication to testing.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3466542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding is not a contraindication to testing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aplisol Intradermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 unit/0.1 mL (1 mL): $46.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tubersol Intradermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 unit/0.1 mL (1 mL): $46.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3466566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for immediate hypersensitivity reactions for ~15 minutes following injection.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tuberculosis results in individuals becoming sensitized to certain antigenic components of the",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     organism. Culture extracts called tuberculins are contained in tuberculin skin test preparations. Upon intracutaneous injection of these culture extracts, a classic delayed (cellular) hypersensitivity reaction occurs. This reaction is characteristic of a delayed course (peak occurs &gt;24 hours after injection, induration of the skin secondary to cell infiltration, and occasional vesiculation and necrosis). Delayed hypersensitivity reactions to tuberculin may indicate infection with a variety of nontuberculosis mycobacteria, or vaccination with the live attenuated mycobacterial strain of",
"     <i>",
"      M. bovis",
"     </i>",
"     vaccine, BCG, in addition to previous natural infection with",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Delayed hypersensitivity reactions: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 48-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Reactions subside over a few days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Centers for Disease Control and Prevention, Guidelines for Preventing the Transmission of",
"      <i>",
"       Mycobacterium tuberculosis",
"      </i>",
"      in Health-Care Settings, 2005,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 30;54(17):1-141.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dutt AK and Stead WW, &ldquo;Tuberculosis,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1992, 8(4):761-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/35/15924/abstract-text/1423133/pubmed\" id=\"1423133\" target=\"_blank\">",
"        1423133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villarino ME, Burman W, Wang YC, et al, &ldquo;Comparable Specificity of 2 Commercial Tuberculin Reagents in Persons at Low Risk for Tuberculous Infection,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1999, 281(2):169-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/35/15924/abstract-text/9917121/pubmed\" id=\"9917121\" target=\"_blank\">",
"        9917121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10029 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15924=[""].join("\n");
var outline_f15_35_15924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232324\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232332\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232325\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232329\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232326\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232311\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232298\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232314\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232312\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232338\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232330\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232317\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232302\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300188\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232306\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232308\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466540\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466542\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324046\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466566\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232301\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232316\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10029\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10029|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/2/15395?source=related_link\">",
"      Tuberculin skin test: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_35_15925="Cardiac resynchronization leads";
var content_f15_35_15925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pacing leads for cardiac resynchronization therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 585px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two leads (right atrial and right ventricular leads) permit pacing of the right atrium and right ventricle. The third lead (coronary sinus lead), which is advanced through the coronary sinus into a venous branch that runs along the free wall of the left ventricle, paces the lateral wall and enables synchronized left ventricular contraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15925=[""].join("\n");
var outline_f15_35_15925=null;
var title_f15_35_15926="Orthodromic AVRT";
var content_f15_35_15926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Orthodromic atrioventricular reentrant tachycardia (AVRT) in the setting of an accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 262px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEGAXQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4/4rW0F54SitbuGKe2n1bSo5YpUDJIh1C3BVgeCCCQQa8d+Meq+GvBXiyy07Rvh34SvrK0t0v9bkk0mJmgt3mSNdmAAG5PUN1U4wDXtHxNEn/CLxyRW9zceRqem3DpbQPPJ5cd9A7kIgLNhVY4AJwK891Lw78PtW1TxLqOs6V4o1K911Qkk134avZGtAEKD7OfsuYyARzyflHpQB1Om6DoGjfE3QZvDek6Xp8V3omoO7WNtHCJgJrEqTsAzjccZ9T616HXmPgqO1j8T+GLDSI/EE2n6PoV7Zm61XTbi2PzS2flqWkijVjtjfhR0WvTqACiiigAooooAKKKKACiiigAooooA5X4sf8AJLPGX/YFvf8A0Q9eQ/FBdF8OePIdB0bwT4P8l9Hk1Hc/hdr6R5FdgE2wldqnA+YjA717H8Tbae8+G3iy1s4ZZ7mfSbuOKKJCzyO0LgKoHJJJAAFcP4lTw/rfiyDxHFfePNL1SGybTw9j4dusGJmLHiSzfnJ6jHSgCp4RstBvLT4XeJNM8O+H9K1C/v5POfSreJQP9AvNyB0GSNyjIycEc8ivaK8m8PW2jWEngHw94S03Xo7HStRmnd7zSbyBUQ2d2C7ySxKuTJKoxnq3Ar1mgAooooAKKKKACiiigAooooAKKKKACvnW30/w/YeFfhPpWn+DvCtxrXiazhD3l/pUcwRUtkeSRgNrO2WB5YZ55719FV4lp0ehap4A8E2OuWfi7T9a0KztfKuLTQb4TWs6QqjgN9nZGGRgghlOO9AGhrHgjTtF0Gzu7vw94Ug1aDXtLEF7pGmLbExm/txnB3MjYLKQHYEd+cD12vKNQ1CC50a00uzk8X6tfz61p1y0+paLdxYVL2B3Jb7PHFGiohPAUcE8kkn1egAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKjuZ4bW3knuZY4YI1LPJIwVVA6kk8AUAMvru30+znu76eO3tYEMkssjBVRQMkknoK8mPxK8S+NZ5IPhV4fSbTwxQ6/rG6K1yDgmNB80n17Ecis2+uJfjh4l/s6xaVPhvpcwN5crlP7WnU5ESHvEDgkj6/3SPbbW3htLaK2tYo4beJBHHHGoVUUDAAA4AA7UAeVp8M/FmsYk8W/EvXmZuTBoipYIv8As5AJYe5HNOf4LW0Y36f438dWlyvKyLq5b8CCvI9q9XooA8cm1D4k/DoGXWETxz4bj5kubSIQ6hbp/eMY+WQD2ye5Ir0jwd4q0bxjokWq+Hr2O7tJODjho27q69VYeh/lW3XjPxF8NXfgLWJ/iJ4EgI2fNrukRfLHfQDlpVA4Ei5LZ78n+8GAPZqKz/D+sWXiDRLLVtKmE1jeRLNE47qR0PoR0I7EEVoUAFFFFABRRRQAUUUUAFcJ42+Kfhrwnerp088+pa2/Eel6ZEbi5Y+hUcKfZiD6Vj/FLxhqVzrEHgPwHKD4pv13XN2vK6XbfxSvjoxBG0e4PUrnpvh98P8AQvAuneTpFsHvJBm5v5vmuLlz1Z3PPJ5wOBQBya+J/itr3z6F4L0jQrYn5JdfvGdmHqY4sMp9jTjb/GqACRL7wLcsvJheK5QN7ZHevV6KAPJbX4t3WgXkVh8UfDtz4bkkYRx6lE32iwlY9P3i/cPsc45yRXqttcQ3dvFcWssc0Eqh45I2DK6noQRwR70zULK11Gyms9Qt4bm0mXZJDMgdHHoQeDXimoWN98DtSGp6O1ze/Di4lxfaezGR9KZj/rYj1MeTyv8AMkEAHudFRWdzBe2kN1aSpNbzIJI5EOVdSMgg9wRUtABRRRQAUUUUAFFFFABUV3cwWVtJcXk8Vvbxjc8srhVUepJ4ArA+IPjHTvA/hqfV9UYvtxHb2yH95cyn7saDuSfyGT2rzzQ/hrqXjl4df+LlzNcu5E1t4eicx2lkOwcA5d8Yzk+oOewBsan8cPBsF29npE9/4hvU6waLaPcn8G4U/g1QH4u3wHmf8K08eeRnOf7OG/b67N2c+1elaVpdho9mlppNlbWVqn3YbeJY0H4AYq5QBwXhD4seE/E9/wD2dBey6drGdp07U4jbT59AG4Y+wJNd7XN+NfBHh7xrYG18R6ZBdgDEcxG2WL3Rx8y8+hwe+a83g1jX/g7qVtY+LL2fW/AdxIIbbWJQWuNOJ+6lwf4k7Bv5cLQB7ZRTY3SWNZI2V0YBlZTkEHoQadQAUUUUAFFFFABRRRQAVn+INZsPD2i3mravcJbWFpGZJZW7D2Hck4AA5JIFaFeNeN4z8Rfi3p/g45k8OaAianrKg/LNM3+ogb2/iIPUE9wKAI9Nbx98U0/tKLUp/BPhKXm1igjDX92naRmP+qB6jH6jBLfEvwu8IeHNFudZ8W+LfFkltAoMl1eavIzcnoAoBJJPQAmvQ/iNcanZeFpJNBuJra7WSMBoLSS4cpn5lVUhmKkjjd5bgdxXm/xW8JeIfiX8DtOgto7xdcguFvfs2o7I5p9okTa2EjVSQ+4ZROgBAOcAHPfD7Rfhh47vZ7Twt4o8Ww6jCvmGNtSlilKdCy7sgjnnHIrvF+BfhWZlOq3niDVk3AvHf6pI6SY6BgMZArxr9mr4Q+LdG+I1r4h8QafJpVlpyS4WcjfO7xtHtCg5wN2cnjgYz2+uqAK2nWNrpljBZadbQ2tpAoSKGFAiIo7ADgVZoooAKKKKACkdVdWV1DKwwQRkEUtFAHkPwdDeFPG/i/4fscWNpINV0lc/dtpjlox7I5A+pNevV5R4sB079orwJdx8HVtMvtPkI7rEBMAfbJr1egAooryr4261qF3No/gLw3OYNZ8Ruyz3C8taWS/62T2JGVHr82OcUAJq3xSvtW1u50T4Y6EfEd3atsutQkm8mxtm9DJ/GfZcexPNIun/ABmu8SXGueDtOJGfKtrSaUD2JfmtjXIrf4Y/DiC38Kppdjb2jRxKb+VEQgn53JeSJXkPJwZEye4rmPihqms+KP2ctQ1HQpJZ7y6gVpGtbcwGSESgSbU3v8uwN0dgy5IJBoAfp4+J9+839leOfBeoy27bZIktSwU+jFCSpq3LoPxf1CN4rrxd4c05JBsZ7HT3kdF7su8/er5W/Zoh1qX4w6G2hCXCOWvGUHYLbHz7+2COBn+Lb3xX6A0Acl8PPAeleB7CdLFp7vUbx/NvtRu23z3Un95m9OTgds9yST1tFFABRRRQAVBf2lvf2VxZ3sKT2txG0UsTjKujDBUj0INT0UAeSfBOabw3rXiP4c38skg0SQXOlySHLSWMpyoz32MdpPvgdK9brybxsv8AY/x98AatGNo1W1vNJuWzjKqoljH/AH2TXrNABRRXL/EvxhbeBvB97rVzGZ5UxFbW6/ennbhEH1PX2BNADvG/jrw54ItI5/EmpR2plOIYQDJLKf8AZRQWP1xgZ5Nccnxdv74B9D+HPjK7gPSWe0W3Vh6ruY5HSrPwt+Hj6fKfFfjQrqXja/AlmnlAZbMHpDCOihRwSPcA4rd8KeL7vWfEV9pWo6UmlywK8kUUss3nyIsmzftaFYypyDlJHA3AHnoAc2fif4lUbn+F3ibYOTtaNjj2GeT7Uh+KfiCYEWPwv8WOwHS4WOAZ7cknj37V8ueJ/jr4+uvGNxqNrrNxp8UMzCGwjA8qNQeFZSMOfUtk/Svt/wAE6vLr/g7Q9YuIRBNf2UNy8Y6KzoGOPbnj2oA4Hwn4J17xB4qt/GPxN+zi9tc/2XokDb4NPz/Gx6PL78gcHsoX1iiigAorA1fxn4Z0eYw6pr+l2tx/zxkukEh+iZ3H8q8f1L9o7T/D/jW/0XXdMln09JQbbUNPzl42GV3RPg5GcEg8kHAoA9/qnrGmWes6XdabqdulzZXUZimicZDKev8A+vtRo2pQavpdtqFos6wXCb0E8Dwvj3RwGH4j36VcoA8l+C93d+G9a1n4bazcPPLo4FzpU8h+aewc4X8UPyn64HAr1qvJPi0g0P4lfDjxVHhN2oNodyf76XCnYG9lYMfqa9boAKKKKACiiigAooooAiu7iO0tZrmdtsUKNI59FAyT+VeX/s52kk/gy78U36/8TPxNfTajMx6hN5WNP90AZH+9XY/EsyD4ceKzAA0w0m7KA9C3ktj9ao/BlYl+E3g8QElP7Kticj+Ixgt+uaAOyoqvf3trp1nLd6hcwWtpEN0k08gREHqWPArI8S6jrMVxb6f4e05Zru4Us15c5W1tVHG5sfM7eiLjPcqOaAN+iuPi8DRXf7zxNq+q61cHkq9w1tbg/wCzDEVXH+9uPuae/gDRYwW019T0u4xxNY6hNGR9VLFG+jKw9qAOtorh5Na1jwew/wCErlTUtCJx/bUUYjkts9PtMa/KF/6apgD+JVHNbnhjxTpXiaXVk0e4E/8AZl21lOw6eYFVjt9R82M+oNAG5RRRQAUUUUAeR/GyddB8Y/DjxZdZTTtM1Ga1uph0hS5jCb29FG3k/wCNetqwZQykFSMgg5BFUtc0mx13SLvS9WtkurC6jMc0L9GU/wAj3BHIPNeQaLf6l8HPEdj4d8QXkt94F1CTyNK1Oc5fT5O1vM3Tb/dPbHYAhQD22vIvhCh8UePPGfjq5yyNdHRdMzyFtoCNzL7O/P1Br1HWro2Wj310ucwQSSjA5+VSe/0rgP2b7RbT4KeGFGC0kUkzMOcl5Xbk+vOPwoA9LoorG8Va7HoGmrP5El3dzyrb2lpEQHuJm+6gJ4A4JLHhVDE9KAFn1zQdM1ZdMuNQ06y1GdRKtvJKsUkoJI3KDgtyCOM1sV8//F34SeLfiPe+HxqeqWKFGle5lihVYbJDsxHGP9bKx5yWYL8vRc4r0jwH8NdH8G+HrfSrK51W4WOVJ2llvpVLOvTCowULyfkAwR97dQB3FFYkttqumCeXT5pNVM92JDb3kyxi3iY/MsTKmTjqFfPpuHFaVhf2moRPLY3MVxGkjwu0bhgrqSrKcdCCCCKALNFFFABRRRQB5P8AHBxZeIvhpqUxC28PiGOB2bgL5qMoJPbpXrFYHjvwrp/jTwve6Hqyt5FwvyyJ9+Fxyrr7g8/oeDXCeA/GOs+HvEVv4E+I5Q6m6Y0rWFBEWpoP4ST92UDGR3+pBYA9arx/XEHjn486fpLDzNG8HQLqF0v8L3sv+pU+u1RvH4ivYK8n+AS/bT4712TmbUfEd0qv1zDFhYwD3A+bmgD1isvSfDuiaNdXFzpGj6bYXFzzPLa2qRPLzn5ioBbkk81qU2R0ijaSRlRFBZmY4AA6kmgDzzWfgr4B1nxHJreoaBHJfSyedKFmkSOV+pZkDBSSeTxyeucnPc6heWuj6XLdXAaO0t05WGJnIHQBUQEnsAAK898UfES6XRrjVtDgFv4cgOJdduLaS4RhyN8EEeGkQf8APRiqdxuHNZ/w61WH4i2V3ead4n8W3cVuQhneOGxgaQjOxAibjjjOd2Nw5NAHWDU/FevD/iT6bDoNk3S71dfMuGHqtsjDH/A3BHdakPgW0vsN4k1LVNdfqY7q4McH08iLZGR/vKx9zXEWnifU9P1Sw0lPEVxB4juJTAdD8QRRyoWCswKXESo2xghCyfOCeCoOVHe6Z400+W0uP7ZB0bULSWOC6s7lgWjkkO2PaRxIrn7rL15HBBAANnSdG0vR4RDpGm2VhFjGy1gWJcfRQKyNP8C+HrLxPfeIxp0U+uXknmSXtx+8kXACgJn7gAAHy44HOa6aigAooooA8p/aT/deAbG7wR9k1iyn3jqmJQMj8/1r1auc+IvhW38a+C9V8P3chiS9i2rKBny3UhkbHfDAHHeuT+Fvjy6uLseDfHELaf4zso8ESH5NQjXjz4m/izgkj6nsQAD0+iiigAooooAKKKKAIL+0iv7G5tLgFoLiNopAO6sMH9DXmH7OV+8fgq48LX7Y1fwzdy6dcoRgld7NG4H90qcA99pr1avJfid4d1bw/wCJY/iJ4Iga41GCMQ6vpi8DUbYdx/00UDjqSAMdMMAYn7Qui6odM1zVdFgn0+AWq/2jeyXuYbyMYAj+zYbLLnh/3ZHPLdD33wz0TUtIGpP4htp21udozc6i9/8AaY70jdgxrhfKVcn5NigbgAW5NSHxlBr/AMLNR8T+D5lnk/s6ee2DrkpOsbEI6+oYAEfzBzXW2dxHd2kFzA26GZFkQ+qkZB/I0ATUUUUAYfjPw9/wk+gXGmf2pqWl+aMfaNPm8qQe2ccj1HevFvhl4MuPgV4m1GXXdf0x/CWqxBBdTzLbuk6ElAUY85VnHylvUgAV9C18mftoeHteu9f0XWLa2ubnQ4rMwExKzrBN5jFiwH3dylBnvt9qAPqC08QaNd6IdZttVsJdIVC7Xq3CmFVHUl84GO+TxU9rqmn3csMdrfWs8k0AuYljmVi8JIAkUA8pkj5hxzXyz8BPBnimX4K/EK1ayuEGsQCPTbSY+UXk8twzgPgANujG44B2+1et+AfBOs+GfiffysgfwsumtHp771zbtJMsj2+M52qwcqcYAYDPGAAer0UUUAFY/i7w7p/izw5faJrEPm2V3GUb1U9Qy+jA4IPqK2KKAPLfgtq99caVq/gnxTIZNe8OP9jlkJwbm2YfuZh9V49eATyaj/ZquGi+HB0C6Yf2h4fv7nTblehDLKzA49MOB+FQfENf+EU+MXgvxZCNlrqzHw/qJHAYv80BPvuByfRQKq+Oorv4YePZfHumwPP4Z1URweIbaIZaFhwl0oHpnBHuf72QAez1yDp/afxUUSZaHRNMEqDt51y7ru+qpAR9JT6102m31rqen299p9xHc2dwgkimjbKupGQQa53w8AfH3i5j97bZrn2EbHH5k/maAOrooooAK8f+J3xf8O/DLxVHZTrLcS3ELT3VlY2ybhIxUJK8hYclVI24JI2nIAG72CvmP9on4GeIPFnjJ/EnhVoLprtI0uLWWURsjIoQMpPBXaBkZzn1zwAeswfFzw5dfDxPGNhHf3mnm4S1a2giU3CTM6qEKFgM5ZTwTwQRmuk8NeLNM8SXl5BpLvMltDbz+fgeXIkyF0KHOeg5yBXlvwn+Ff8AZHw7k8OXGrxHVbbXbfUL8xRM6RSxGCYQjO3OUCHd/t98V3nw/wDAFt4K1nxLdafds9nq86TRWhTAtANxKKcnKlnYgYGOnPWgDtaKKKACuU+Jfguy8deGJtLu2MF0p86zvE4e1nX7sinr1646jNdXRQB5/wDBnxdeeJNButP8QKIvE+hzmw1OP+86/dlGOzgE5HGQccYrH/Z9b7Jb+NdEkG2bTfEd2oTP/LJyGRvofmqHxmv/AAhvxt8NeJYj5en+JB/Yeojopmxm3c+rHG3PYLVbxnO/wy+Kq+MnVz4V8QpFZawyjItJ0+WGdgP4cfKf+BdSQKAPZ6434ha5pNhZXsWvfbU0yzs21C9McamGeIHYLd9ww3mEkbOM4wTg4PYRSJLGkkTq8bgMrKchgehB7ivIfjd4cXxV4f1u2vNdmNlb3FoF0+12gpKxVVEhwSQTKGxx/Ce1AHZ6h4P0PxQI7vUHn1DT5IF+yWrSYtYFKjDpGAFLdCGcMVP3cdK2vDWh6f4a0Ky0fRrdbewtIxHFGP1JPck5JPckmoPBWht4Z8LaborXsl8tjF5Ec8ihWMakhAQO4Xaue+M4HStqgDzjx78INB8X65Brsl1qdhr1u6SQXttcs2xkOVwj7lABGcKBXkvxv+EuvxeKtL8UaXqOpaxpiXULXVrcTyTPZgOCWTcxPlZLHGflyeoyR9Q14L+0/wCJNVb4da/YaGtzbvY6hbQX7xnlrSSHfvyOQpkIjPrtI6GgD3hHSQExsrAEjKnPI606vhv9kO81mP4s29tpzznS5reU6gi5MYQIdjMOgIfYAevzEdzXtvxR8PeIJPGfirxD4ds7uW7tdGtoY41jbZfwv9oWeBcD5nAMbgDJDKvHNAHu9FYngaGW28E+H4LiJ4p4tPt0kjkUqyMI1BBB5BB7Vt0AFcT8VPAkHjbRY/s8v2HX7B/tGl6inD28w5HI52kgZH0PUCu2ooA4X4ReNJvF2gTw6vCLTxJpUpstVtemyZeN4H91sEjt1HOM13VeP+O0/wCEG+Lvh7xhbDy9M15l0XWAPu7z/wAe8p9CCNpPoMd69goAKKKKACiiigAooooA8O8KT3fhnx18YrPw9oy6pBaXFjfJpkcgi3tPAzS7OCCTgfLgZx9BWR+zF4+1fxRrmpaLeq0Gl6Np8Vva2zj50CuVBcnkvt2qf93oOc9l8Lfn+LvxYlk/15u7FCCcnYsB2fhjNXLDwlrM3jW/8R2kGneGJb2NYLkw/wCl3F0itkM2QI437ZxJx+gB6VRRRQAUUUUAecSX2qQfErW5PCukHUrf7LDDqRluBbxJdINyBGIYs5ikAYYAAEfPWus8MeI7bXkuYxBPZajaMI7uwugFmgY9M4JDKRyrqSpHQ8HGZ4IYW+ueL9NfAni1MXQ9WimiRlb/AL6Ei/8AAKd420m5Elt4j0KIvrmmKcRJwb23PMlufXONy56OF7E5AOsoqnoup2ms6Taalp0omtLqNZYnHcEd/Q9iOx4q5QAUUV4n+0V8Vpfh9e+F7TTm3XM12t3eRjqbVDgp7byTg/7BoA6D9o+we8+EOtT25K3enmK/gcDJRopFYn/vndXe6dcQa3oVrcvGkltfWyyGNwGVkdQcEdCMGuc+J09tqPwe8VXVs6T2s+h3U0TjkMpgZlYfoas/Clmf4XeD2dizNo1mSScknyEoA4n4SWx8JfEjxl4Is5JW0K3SDUtOhdt32YSg+ZGCedu7oPY9ySe00gGH4l+JIyCFm0+wuFPYnfco34gIv5iuU8I5uP2h/H0ueLXTrCDAHXcpfmuO/aH8fa54F+J3g650NHuUa2lWaxG4i6VpFGwgd+BtOMg+vSgD6HorK8La3D4i0G01S3t7u1WdcmC7haKWJu6sp7g/geoyK1aACiiigDnYn1O/13ULnTNXtDpsEDWi2bWxbbeAkl3fIOACo2jr6jvoaLfyXEX2XUHs11m3jRry3tpS6xls4IyAdrbWIyOx9KZosc8V5rCS2EFpB9r3wSRY/wBJVo0LSMB0beXU56hQe9R61FPbXtpqWnWti0okSG+mn+VxafMTtfPG1iHwcjAYdSCADZooByMjpRQAUUVla9cxwS6VHJeTWrXF6kUflrnzWCu/ltxwpCnn2oA4v9onTJNR+Eety22ReacE1GBx1RoXDlh/wEN+dddaGw8YeDbZ762iuNO1eySSSFuVZJEDY/XrR44t0u/BXiC3lGY5tPuI2GM8GNga5/4FTvcfB/wk8nLDT40H0UbR+gFAHNfDNr7wJ4/ufhze3TXuivZnUtEnlbMkUQfa1ux77eo9h7gDtdb1Wz8OSeJNW1jT1g0u1tYLqS8UBmuGBcFceqbUx/vCuU10+b+0n4YRASYdCupX/wB1pAo/WtD4ueFrXxVHZ6Pdatfaeus/6ARCu+OTYftOOThWIhcBueCRg0AegWV1Be2cF3aSpNbTxrLFIhyrowyGB7ggg1NXBfAzSl0j4X6Hbx3V3PG0CyeXdMGa3cgb4lIA+VX34zyOnYV3tABXiN94T8Uw/tC6bfXWoXV/4RvYZGdCqqimOOXZBLtA3ANMzKWzkHHO2vbqKAPO9budL8A+J9AGmWcNnp2pfaILnT9MsN8jsFV0nEUKl22lShIBx5q5x1rstC1zTtetXuNKulnSNzHIpUpJE46o6MAyN/ssAawrJVHxZ1gzgGVtGs/szHsgmuPNA/HyifX5fSm+M9MudPuh4r0CF31SzTF3axf8xC2HLRkd5FGWjPrlejGgDsaKq6VqFrq2mWuoadMk9ndRLNDKnR0YZB/KrVABRRXkfx2+K8fw7vfDNpCytPeXiS3i7dxWzU4cj0JJ4P8AstQB0nxu0IeIvhX4jsgpMyWrXMGOoli/eLj0JK4/Gtb4da5/wkvgTQNZZt0l5ZRSS/8AXTaA4/76BFb/AO7uIeqyRSL25DKR+ory79mZmj+E9pYOWY6deXdpuJzkLO5HPf73tQB6pRRRQAUUUUAFFFFAHkV8/wDwiH7Q9tdyfLpvjGxFqz9heW4+TP1jwo9SfavXa4f4x+EpvGHgm4ttOcw61ZSLf6bMDgx3MfK4PbPK57Zz2q38LPGMPjjwbZ6sqiG8GYL236GC4Th0I6jnkexFAHW0UUUAFFFFAHF+Ln/4R3xNpnijO2wkUaZqh7JEzZhmPskjFSeyysT0rtKhvbWC+s57S8iSa2nRopYnGVdSMEEehBrlfA93cabeXfhLVJWludOQSWM8hy11ZE4Rie7of3bHqcKx+/QBDpY/4RTxpLpR+XRtcd7qx7LBdgFpoR7OAZVHqJfau2rG8X6GPEGhT2SzG3ulKz2lyBk286HdHIPXDAZHcZHQ03wbrh1/Q47meEW9/E7W17bZz5Fwhw6fTPIPdSp70AbdeafEzwX4d1LW9Gv9Q0m2vNQv9Rt7SSS4XzN0Ko7FAGyFGFYnGMn3r0uuS8Vt9p8ZeC7AclLq41B19Uit3j/IPcR/jigDJ+J1pY+Ffgb4msdOi8iwt9JntoY2dn2B0KBQSScDdgc8cV0Pw5tWsfh74XtJM77fS7WJs+qxKD/KuK/aRle78Fad4bt2P2jxFqtrpyheu0yB2P0GwZPvXqsaLGioihVUYAHQCgDyaaT/AIRr9pFHnJWy8V6SIo3PQ3Vuc7f+/Z/Nq73xN4V0vxDbXwvLdBd3Nm9iLrbmSJGOflPYhsNx3Uegrmfjl4bvdd8HLfaEp/4SHQ7hNU04gZJkjOSmO+5cjHc4rpfAXiiz8ZeEdM17TiPJvIgzJnJjccOh91YEfhQAeBtXm1jw/E1/sXVrR2s9QjXolxHw+P8AZbh19VZT3rfriPE+/wAJ6+fFUCk6TcokOtRqM+Wq8R3QH+wCVf8A2MH+DFdrG6SxrJGyujAMrKcgg9CDQA6iiigDB1RLfTfEVjqpgvZZ7zbpjmH5o41JZ0eRewDDbuHTzOeORs3VvDd2s1tcxrLBMjRyIwyGUjBB9iDUep2rX2m3dolxNbNPC8Qnhba8ZZSNynsRnIPrVPw/qMV7BPai6Nze6dILS8ZojETKEUltvYMGDDGRhhg0AJ4aZ0spbFtPmsYtPlNnAJJDJ5sSKuyQMeSCpGc8ghhk4ydasHWRb6XrNrrUp1BzIE014oPni/eSrskdeo2tkbh0DnIIwRvUAFZmpfam1bSEt/sptxJJJcCXmTaIyAYx67mXJ9D71p1ibIbjxrvewn+0WOn4ivSSIis8nzxgdCwNshPcAr0zyAO8azLb+DdemkzsjsJ3bHoI2Nc38Bo2i+DvhJXGCbBG/A5I/Q1B+0Hqv9kfB3xNIuTLc232JFHVjMwjwPwYn8K7Dwrpn9i+F9H0odLGzhtev9xAv9KAPOvFcg0b9onwdqNxgW+r6Xc6SrnosiMJQD6E5AHrXpWuw38+myLpE8VvfqyPE8q7l4YFlPBwGUMuQMjdkc1xfx18OXWveBJbrR8rrmizJqunsoy3mxc7R65XcMeuK6XwJ4ltPGHhHS9e0/AhvYQ5TOTG/R0PurAj8KAL9hqmmXK2i2N7aSC6h+026xSKfNiOD5igdV5HI45q/XiHxf8Ahtqniu40ay0FrTQ20u73aZexTmMiKSFmlXAO4Oska/d42vn+Fq9J+HeofbvDEEU73x1CxY2d6l+6vPHOoBZXZQA3BUhgAGUq3egDpqz/ABFDBcaBqUF5bTXVrLbSRywQrueRCpDKo7kgnitCigD548B/ESTXkt9faKTy/CXlaZqd1IpR7m3mLLJMyn7oUxW8pB5GJRX0ODkZHSsS28K6NbX2t3UFjEj60qrfoB8k+Ay5K9MkMQfWsz4eXElpa3Xhm+leS/0RlhV5Dlp7VsmCXPf5BsJ/vxvQBB4XH/CN+LdR8NNldPvA+qaXnogLD7RCP912DgekuOi12tcr8RrSc6NDrGnRtJqWiTDUIUXrKqgiWIeu+IuoH94qe1dHY3UF9ZW93aSLLbXEayxSL0ZWGQR9QaAJ68k+Jnw48MeI/HHh+41mxe9u9TumgnMk7jZbR2kx2xgEbR5nlnPXJPPIr1uuSum+2fFTT4Rymm6TNO49HnlRIz+UEw/E0Ab2g6ZFoui2OmW8s8sFnCsEbzsGcoowuSAMkAAZ9q84/ZtIbwFfspBVtZvSCOhHmmvSdc1CPSNF1DUpyBDZ28lw5P8AdRSx/QVwX7OVhJYfBrw4J8me5jku3J/i82V3B/75YUAelUUUUAFFFFABRRRQAV4t4zhn+FXjuXxvp0MkvhTWHWLxBbRqW+zy5wt0oHbJw31Pdhj2moru2hvLWa2u4kmt5kMckcihldSMEEHqCKAEsrqC+s4LuzmjntZ0WWKWNtyurDIYHuCDU1eM6Lp2t/CPWpdO062v9b8D3xZrGGNTJJpk5OTGzdRCwzhzkA43YyWN7w58XLjxJr0OlaP4alkmdvneS7CrEg6u2EPA/XoKyqVoU2oyerO/CZZicZTnVoxvGG7ulb72j1ZHWRFeNgyMAVZTkEeop1fKOteGPGvg34zapaeCtT1ew8NNGNXaO1j+0pHCzhZAluxCuVcthR820cZPB+nvD9/banotneWV/FqEEsYK3UeNsp7nA4HOeO3StTgNCuY8eaTdXdjb6roqA69pDm5swTgTcYkgY/3ZF+X2O1uqiunooAo6FqltrejWWp2LE211EsqbhhgCOhHYjoR2IIrlvET/APCIeJf+EkAI0S/CQavjpA44iuj7AfI5/u7GPCGrHgZP7P1jxXo6cW1vqH2q3UdES4jWVlx2/emY/wDAhXWuiyIySKGRgQysMgj0NADHuYI7Q3Uk8S2yp5hmLgIFxndu6YxzmuQ8Hl/EHiK/8WPG6WLwrY6V5ilWe3B3vNg8gSPtxnqsaHvVqP4e+FY5EK6PEYUbelq0jtbIexWAt5Yx1GF4qb4h+K7PwR4P1DXL7BW3TEMI6zSnhEH1OPoMntQBwty48Y/tDWsEZ8zTPBlk0spBypvLgYVT24QZ9iDXr1effBHwteeHPB5udcJfxDrM7anqTsORLJyE9towMdM7sda9BoAK8SEn/CnviTL5x8rwH4puN6v0j02/PXPZUfH0GOwU59trL8T6Dp3ifQrzR9atlubC6QpIjfoQexB5B7EUAabqrqyuoZWGCCMgiuBikf4cz+ROJJPBcr/uJgCx0gn+B/8Ap39G/wCWfQ/LgjmPBPiHVPh3r9p4E8dTPcafOfK0HXGHyzr/AAwSntIOAPXgehNjxF8Wrqy1+bw+nhcXd6ZPs+wXiushPAAAQ5znoce9ZVa0KSvNndgctxGYScMNG7Su9UtO+rR66rBlDKQVIyCDkEUtc5pcOo6PBpkEVjG1pM0j3o+2M32IkblWMMPmjByu0Fdo27RgYG1pt/aanYw3unXMN1aTLujmhcOjj1BHBrVanFJWbRZrG1eabT9Usb6TUYLbSTm3uIJUH7yWR41hZWxkHd8uDwd/qBWzVbUrSO+sZreaGCdXXhLhN8ZYcqSO+CAfwoETTJ5kTx7mTcpXcpwRnuD61k+F7pWsn06XUW1DUdLKWl7O8RiZ5fLVtxXp8ysrZGRz+FXdGlvJ9HsZdUgS31B4Ea5hRtyxylRvUEE5AbIzk9Khu7a+XV7K5sJLZLP94L6Fo/nm+UeWyt/eUqBg8EMe4FAF64mitreWe4kWOGJS7uxwFUDJJPoBWX4XzPYy6kL64vINTcXsAmjMfkxPGgSMIeVAABIODuZiQCahibVdZFhM0Nzolskrm7sruOCWW4TaQq7kd0VSTk4O44xxmti8uYLGznuruVILW3jaWWRzhURRkknsABQB5T8WT/wkvxG8CeDIvniW6OuagvZYYM+WG/2XclfqBXrleRfA+CfxJq/iL4j6jC8b63L9m0xJBgxWMRwvHbeRkjuVz3r12gArxXR3/wCFUfFKfR5x5fg3xXObiwlPCWV8fvw+yvxj8AOjGvaqwPHXhTTfGvhm70TWYy1tcD5XX78Tj7rqezA/4dDQBo6zpsWp2bRPsSdQzW9wY1d7eQqVEiZHDDccGvnr4YfGfxvdeNp/BviPw/Bq+pWszwTT2siW0i7CQzFXIR+hPG3jmu7+GnjHUdI1oeAPiDJt8QW640/UH4j1WAfdYE/8tAByOpx3Oa7DUvA2h3x1WX7MYLzUZ47t7uBtk0U8aBI5I2/hZQPxy2cgkEA3bbUrG6up7a2vLaa4gbbLFHKrPGfRgDkH61br5v8AGPw3fxR8T9IfXZ4dO8RQxMPtgiIttYEYzFIoUghx92SMMGC4KnaMj3zw3cajPpaf2zpyafeRMYmjimEsbY6PGw52nsGAYdx6gGpXmGsa/E1vpvjSOI2N9pM8thrFk7guIAcTqSPveWQsyt3QEjG+vT68Vtfhjq2n/G7+3bm+n1jw3qFrcRSpcNl7dmjC7G/vKVUKH64UKegJAPaQQwBBBB5BFcd4Df8Asi/1bwnL8o05/tFhkY3WUpJQD2jYPH7BEz1qx8MJpm8F2VrdOz3GnPNpkjucs5t5WhDH/eCBvxqXxhol5evZatoUkUWvacWNuZiRHPG2PMgkIydrYBz/AAsqnnGCAdLXH+A2Op6p4l18kGK8vfslqfWC2Bjz7gy+ew9mFV7/AFzxBrVk2l6VoOp6PqNwDHNfXgi8myXozqyufNbrtC8ZwW2jNdXommWui6RZ6Zp0flWdpEsMS9cKowMnufU9zQB59+0VqU1t8NbjSrDnU9fuItItUH8TSthh9NgYfiK9B0TTodH0aw0y0GLeyt47aMf7KKFH6CvKy/8Awnfx9QR/vNE8EwkscZWS/lGMe+xR9Qy+9ew0AFFFFABRRRQAUUVkaxqd3bTpa6bpk97duu4MT5UEYzjLyH6dFDN7d6TaSuy6dOVSXLH/AC/F6GszBVLMQFAySeMVzsniYXsjQeG7VtVkB2tcBtlrGfeXB3Y9EDH1xR/wjsmplZPE919uxyLKMFLVT7r1k/4GSPQCuhjRIo1SNVRFGFVRgAegFR70vL8zo/cUd/ff3R/zf4fM54eGzqEizeJbo6kwORaBTHaof+ueTvPu5b2Ari/E+ieJfBOqP4h8B2VrqtlKWfU9JddtxOMjBil5OVA4Xvlj8xIx6vRTVOKd7akzxlaUXBy919Fou+y031OS8A+PvD/jm2eXRrnbfQjbc2Nwvl3Nuc8h0PPXuMj3o1LwnNbahcar4RvV0rUZ233EDp5lndt6yRAja5/56IQ3ruAxVDx58MNG8VXiarbyT6L4kh5g1fTm8uZTjA34++O2DzjgEVzCeL/H3gP9x460F/EekR8DW9ETMoX+9Nb9j3JGFHvVnMdonivU9PAj8SeGNShYdbjS1N/A3+6EHm+/MY/GnSeN4pgU0jQfEmoXJHyxtpc1mufd7hY1A/E1F4V+J/gzxSqjR/ENi85/5d5n8mYHuNj4Y49gRXZUAc54N0m/shqOo640P9rapOJ5o4GLR26qgRIlYgFgqrktgZZmOAMV0dFcn4z+IfhbwbAza/rFtDMPu2qN5k7n0Ea5b05xj3oA6e6uIbS2lubqWOG3iQySSSMFVFAySSeAAO9eL6Csvxi8dW/iK4jceA9BnJ0uJwR/aN0vBnKn+Bf4c9/+BCh9N8S/GS4jOv2l14b8AI6yLp8h2Xmp4OV83H+rj77ev14YezWNpb6fZwWljBHb2sCCOKKNQqooGAAB0FAE9FFR3Mogt5ZikjiNC5WNSzNgZwAOp9qBpXdkSVkatr9np9wtoolu9RcZSztl3ykepHRF/wBpiB71R8vXNc/17Pomnn/lnGwa7kHuwysX0Xcf9oVr6TpNjpEBh0+3SFWO52HLyN/edjyx9ySaz5pS+HQ6vZ0qP8V8z7Lb5v8ARX9UzGfSNT10q+vTCzswdy2Fm53dMfvJuCeCeE2jnGWFeaXzTfCvX7fVvE+nTazoiySwwaxZ26INLt22lUkgjUZO4yAyDqCO5217lTZY0ljeOVFeNwVZWGQwPUEdxTVOO71YnjKtuWD5Y7WWi/4Pq7t9yro+qWOtabBqGk3cF5ZTrujmhcMrD6j+VQPpJjvrObT7p7GCJ5GmtYYk8q538ksMZDbudwI6nOc15rq3wv1LwzqU+t/CXUU0i6kbzLjRbnLafdH2Ucxt7jjsNozVnQfjHpseoJo3j6xn8I6908u+/wCPabtujnHylfc4Huas5TtovEItbO2fxFaPpFzPcfZkjZhMjPn5SJEyArdi4U+wqS78TabHHqa2Eyarf6cAJ7CwdZrhWY4VSgPyknu2AOSSACa14Jo54UlgkSWJxuV0YMrD1BHWn0AZ+gadDpOkW1lbJIkcYJCyMGYFiWIJHXkmtCikdlRWZ2CqoySTgAUALXjPxP1C4+IPiiP4a+HZnWzQrP4ivoukEAORAD/ff0/mN2J/FnxEv/FGpTeE/hQUvdSPyXutjm005T1Ibo74zgDIz6kEDt/h14K03wL4fGnaaZJ5pHM13eTHMt1MfvSOff07fmSAdDp9nb6dYW1lYwrBa28awxRIMBEUYAHsAKnoooAKKKKAOX+IXgjSvHWiiw1USRTQuJbS8gO2a1lHR0bt0GR3/IjhfDvj7V/BOp2/hj4sFUaRvL0/xEi4trwdllP/ACzk9c8evqfYqz9e0bTvEGlT6brVlBe2M4xJDMu5T7+xHUEcjtQAzXtF07xFpZs9ShE9uxEiMrFXjccrJG45Vh1DAgiuaTU9c8I5g8QRXWtaKvEerWsW+5iX/p4hQZbH/PSMHPdV6njh4f8AGnwqJfwc0vinwenJ0W5fN5aL3+zv/GB2U/QAnmu68B/ETw542hYaPe7L+PIn0+5HlXMBHUNGeePUZHvQB5jp7/Ea7+Idtd6H4sh8U+DmVriMxSQQA7SP9HleOJtr/NnoN20jKnOPXT4ptrHQX1PxJBLoQjYo0N5JGzMw6bPLZt+7+ED5j6Z4o1bwZ4c1a8a8vtHtGvW4a5RPLmYehkXDH86TSfBXhzSb1Lyy0e1W9QYS5kUyyoPZ3yw/A0AQ/Du1u7fw9JPqFu9rcX15c332eT78KyzO6K3+0FK5HY5HaunoooAK4b4u+NW8HeHFGmx/avEWpP8AZNKs1G5pZ24Bx/dXOT26DvWj8QfHGj+BdG+3avKWmlOy1s4vmmupOyIvU8kc9BnmuS+GvhHWNS8QP49+IEaLr88fl6fpw5TS4Dn5R/00IPJ6jJHcgAHSfCjwcPBPg6206aX7RqczNdahdE5M9y/LsT1PYAnsorsaKKACiiigApCQoJYgAckntS1Bf2kN/Y3FndKzQXEbRSBXKEqwwcMCCOD1BBoA8Vs/jTNf6D4xvbJ9FkmsLU3+mpHJ5v7jzni/0hVfIf5UcgbeJV967/4ceJ7rxGdZSe603UrexuFig1TTI2S2ugUDEKC78qTgkOw+nIrQ1fwT4e1exs7PUNOWS2tLZrSBFlePZCwUFMqwJGEXr/dB610VABRRRQAUUUUAFFFFAHLeKfh74S8VMz6/4f0+8mbrOYtkp/7aLhv1rkR8CvDFtldG1LxNo8XaOw1WRFH/AH1ur1eigDyk/BHSp+NU8U+NdTU/eW81hmDj0OAK6Twn8MfBvhOZZ9D0CzhulORcygzTA+odyWH4EV2VFABRRRQB5l8SfibH4Q8W6PpYm0tIGVLjUPtcwSUQvMsS+SNw3MMu54PyxnjkVVsviJqc3xBm0UXGjXCJrL6b/ZkMTi9SAQh/tTN5hGwE4OYwOOGzxXoM/hzSp31lp7RZDrEaw3292ImQIUC4z8o2k8LjqT1JNP0DQdO0CC4h0qBoUuJfPl3SvIWfYqbiWJP3UUfh65oA06KKKACiiigAqhrejabr1g9jrVha39m/WG4iEi59cHoffrV+igDyeX4KafpkzT+BfEOveFZGbcYbS5Mtsx9WifOfzx7UqaB8X9P+S18Z+HtWQcB9Q0wwt9cRHGa9XooA8p+xfGm6GJ9V8D2OeN1rb3EpHv8AP3qGT4R6n4ibPxE8b6vrtsTubT7RFsbVvZlTlh75Br1yigDO0DRNM8PaZFp2h2NvY2Uf3YYECjPqfU+pPJrRoooAKKKKACiiigAooooAK4rxz8MfDHjOZbrU7JrfVU/1WpWTmC5jI6EOOuO24ECu1ooA8jXw98VfCoxoHibTfFNivS21yIxXAHoJk+8fd6kX4jeNdPOzX/hbq4I4Mml3cV4G9wBjH0zXrFFAHlP/AAty/lylr8NPHbTLwwm09Yk3dsMW5HvUU2vfFjxIDFonhbTfC1u4x9t1e7FxKB6rFGOG9mBH9PW6KAPO/BPwtstE1f8A4SDxDqFz4l8VMMf2lfdIfaGPpGOfcjtjOK9EoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDD8La2daGrFlRfsWozWQ2jqIyOTz15rcrzr4LymS08UOzE+drc1yuf7sscb5/MtXotbYiChUcURTlzRTYUUUViWFFFFABWG2syDxtHogSPyjp7XjNzuz5ioB6Y+9W5XBWUon+N+pjcc2uhwxbc8fNMzH8ela0oqXM30RE3a3qd7RRRWRYVjeKtXfRrG0liRHkuL+0tAH6YlnRGPXqFZiPfFbNcD8XbgwxeD4wf9f4lsEI9g5b/ANlFa0IKdRRZFSXLFs76iiisiwqpq93/AGfpN7eYU/Z4HmwxwPlUnn8qt1zvxEdk8BeIdhw72E0an0ZkKg/mRV04800u5MnZNml4dvZNS0DTL6ZUWW6tYp3VPugsgJAz25rQrn/h5I0vgDwzI5yz6ZbMT7mJa6CiouWbXmEXeKYUUUVBRjaVq0l74g1uwZFWPT2hVWAOWLx7znn3HpWzXnvgGUz/ABI+Ikh+79otFGOh2w7P5rXoVbV4KErLsvyRFOXMr+v5hRRRWJYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFeL/FfWI9P8TXr3GvnENnEYdLh1qfTLpHyxLQIqlLp2+UBGyARjvXsls2+3icrIpZAdsgww46H3oAkqvqF0llYXN1Ljy4ImlbJxwoJP8q8y8eeL9Sl1mPTNKhW2tNP8QaVZXd2b5opnMssLlEiCHchRwpLOufm4IFdX41mOpmLwvaZa41JD9qYH/UWmcSMfdhlF9SxPRTV0480knsTJ2VzJ+E1tJYwXdpN/rVtbCST13m2UN+GU/nXoFc3poEXj/XIhgK2nWUijp/HcqQPptH510lXiJc0+bvb8kTTVo2CiiisTQoa/q1poOiX2q6i5Szs4WnlIGTtUZwB3PYD1qDwtrtt4k0ODVLOOeGOUujQ3ChZYnRyjo4BIDKykEZPSqHxC0S217w+LTU9Q+w6UlxHcXrbinmxRtv2eYGUx5YLlgc4BHfIq/DvSdO0yLVpdA1Zr/SLy6+0RxvM87wSlQJQZXZnYswDYbkEn1p2dr9BXWx19ec+GP3nxj8WT9f3UcKnHVVjhP/oTPXo1ec+Bxv8AHOrXGP8AXfbOfXZdtF/7T/yK6KGkJvyt/X3GdTePqejUUVl+KdbtvDfhzUdavkmktbCB7iVIQC5VRkhQSBn6kVzGpqV518Vle41rwdbxru26nDdNyBgJcQLn3/1mPxrpvC/ieHXrm/tDYX2nX9j5ZntbwR7wsilkYGN3UggHo2cg5xXMfENvM8VaSAebcWnf/nrqdn/8arpwn8VMyrfAz0aiisvxTrdt4b8OajrV8k0lrYQPcSpCAXKqMkKCQM/UiuY1NSuc+IPzeGXiH/Le7tLf/v5cxJ/7NUnhfxPDr1zf2hsL7Tr+x8sz2t4I94WRSyMDG7qQQD0bOQc4qLxr866HABzNqtv/AOOEyf8AtOtKP8RMmfwsX4cceAfDydo7GGMfRUCj9BXR1znw748F6UnaOMxj3CsVH6CujorfxJerCHwoKK43wz8QbHX9RtbVNN1SyW8+0CzuLpYvLuTA5SQLskZgQQT84XIHFdlWZR5z8NOfGHi6UHidxIeepW8vos/lEv5fWvRq84+GJ/4ms0vUXemQz9MYzd3j8ex839K9Hrpxf8V/L8jKj8CCiiiuY1CiiigAooooAKKKKACvI/jL4u1Dw9428E2EWtX2kaNqCXz6hLY2aXM22KJXVgrRSEAHOcL0JJ6ZHrlZGp+G9J1TXdJ1m/tBNqOleaLOUyOPK81dsnyg7WyBj5gcdsUAeAWXjLxhqa/Ce9n1FppdT1K9VQk/2aO+gXaIvPEQKg9cjacemc122nfG23l0fw9q2qaK1hpeoXtzp13cm63rZTxglR9wbw+Dz8uMHg11mmfC/wAH6XdWE9hpJhewupL21UXUxSGVwA7KhfaAQB8uMcdKy/F3wl0fV/AbeE9HZdI02W+W9mJRrhmO7c4Uu+VLHvk4GRjmgDktI+JXi3xB8QPAyWWn21hpOt6dPeNp890CXQM22QyCEsDsCsFHBzgkdazfgr8SdVtNI8MWGvx3Gpx67ql5aR6jNfNJNE6HIVkZTlOQAQ/HPHr7LqHgvQb+/wBIvZrJ47vSU8uymtriWBokwBszGy5XAA2nIx25NUtO+G3hPTk0lLPSvLXSrqS8sx9plPlTP95uX+bOOhyPagDhtG+NV7qlzoEcfhmBF1q8urC2ZtTPyywkffHk8IcjkZI54PGe1+HvjtPGPgI+JItNnhkTzlksom8598ZIKocDcTgY4HXFSWHw38KWD6U1ppXltpdzLeWZ+0SnypZcb25bnOBwcgdgK0/DvhTR/DmhS6NolrJZ6fI0jFI7iTcGf7xDltyn3BGO2KAPFvEHxs1TVvhr4i1Lw8ml6Vq1hFHKYWvWkvLZTMqEvBJbBT94DhmHzdemeom+J3iOy1fw74fj8Jxavrmo6Uuot9m1RI0A3lSSZI1H3RuOOhO0A43V1h+GvhR49TW606W8bUoBa3Ut7ez3MskQIITzJHZ1AIBwCOQDVzTPA3h/TdW0/VLa0nbULC1ayt7ie8nndIWYsUy7nIyTjOSBgDAAFAHmmg/F2/caTaQ6XJqN5q2s32mwtfX6RCIw7SMmK3Hynd/dLDHVq9E+GfjJPHHhx9SFk1jcQXUtncW5k8wRyxnBAfA3DBBzgda53W/g7o15qXh6XSp5tKs9Mvri/mggkl33EkwUMVlEgeI/L1U/TFd14a8P6X4Y0iHS9Cs0s7GIkrGpLEknJJYklifUkmgDUrO1/WLTQ9Oa7vWYjISKKMbpJ5D92NF/iYngD+lV9T0SS9u2nj1nVbMMADHbyIE49AyHH4UzS/C+m2F+L8rPeagAQt1ezNPIgPUIWOEHsoGa0ioLWT+RDctkUYrTxdc2gupdU0+yu2Xetitp5sUZ6hHk3bmPYsuPYeuj4Y1sazayrPCbTUrV/JvLRjloZPr3UjlW6EfiK2aydX8OaRrFwk+o2EM86L5YkIIbbnO0kclfY8U+eMtJK3ov6uHK1sc34jbw7c+IFOn6DpeueLYtmyQ20btalTuRpZsExhSAQM7uPlBNdB4Z0VtKiuJ72f7Xqt4wku7nGAxH3VUfwooOFH4nJJJ0NN0+z0u0S1020gtLZPuxQRhFH4DirVKU0lyw2/P+uwKLvdnNSOtv8RoQ52/bdLZUz/EYpQSB74mz9M+ldLVDWNIsNYt0h1K2SdEbehJIaNv7ysMFTyeQQeayP+EXmtADo2vavaEdI55/tkZ9iJtzY+jA+9P3ZpXdn/X9bBrHodNRXLHWta0cgeINM+123Q3+ko0gX3eDmRe/3TJ74pt14ok1MC08J28t3dycG6mgeO2th/edmA3Ef3F5PfA5o9jJ7bd+ge0Q/wAXqt/q3h3SWw0c14budDzujgUuOPTzTDRprR2fxC1q1Lqn26ztryNM4LupkjkIHfCrDk+4q9oXh620qZ7t5Z73VJUCTXty5aRx1wB0Rc87VAHtT/EPh+x10WrXYljubSTzba5t5DHLCxGDtYdiOCOh7ir54r3L6W/W/wDkTyv4upr15z4CH/E00SYDBudLvLg+++6Rx/6Gfzqx4p8Ojw74b1DWPDd5qVtqNjbPckG6eZLooCxEqSFgxODyAG54NXtC8L2F74Q8MJeLcrcWOnRQxTW11LbyKDGgYbo2UkHauQeOBxVx5IU276PTz2f+fcTvKVrao7CsTxtoX/CT+EdY0P7T9l/tC2e28/Zv8vcMZ25GfpkVk2GrzaFp/imPUpprtNDDXMUkpzJJbmHzAGPchhIuepCjOTmpdN8JtPZxT6/qOrz6pKA9wbfVLm3iRj1REjkVQo6DjJxySaydJR1k9P6ZfO3sjT8NeG9N8ORTrpsc3m3LK889xcSXEsrBQo3PIzMQAMAZwO1cj4wO/wARapKc7LY6GD7f8TBnY/lt/I10v/CHaZ/z9a9/4Pb7/wCPVyvgfRX1GLxvp2q3F1JENUa0ilaZmmSNFWSI72ySyiRcMc/dHWtaPJG809rdPNeZFTmdotf1Y9MrE8baF/wk/hHWND+0/Zf7QtntvP2b/L3DGduRn6ZFZVzDq2h6tobP4gv9Rt7u7NrPBdw24GDFIwZTHEhBBQdSRgn61IV1LW/EmsRW2t32m2WnmG2CWkdu2+Up5jljLE5+7JGMDFZey63VrX697di+fyNPw14b03w5FOumxzebcsrzz3FxJcSysFCjc8jMxAAwBnA7VU8TfvPEXhOHqFvZZyMdltpl/m4/HFO/4R7U/wDocNe/782P/wAj1zti2oxfFa00fUb2fUYrXTptQgupkRG2u0cWxvLVVJBDnOBw3eqp01dtSTsn37ehM5bJrqjofh7x4UtkP/LOa4iz67Z5Fz+ldHXD6tpt74T0i41HS9bv5LW2mN09hPHA0JjaXfKoIjEnRnIO44OOvStDUptQ1bxO2k6ZqFxptrYwLNd3FukTSO8hIjjXzEZQAFZmOM8qPWidPnk5p6O/9fiEZcq5WtSp4G+H2m+FQlwXlvtTQz7bmaWQrGssrSFY4mdlj6gHYBu25PWuvuZhb28szfdjQufoBmsH/hHtT/6HDXv+/Nj/API9cz8SbLWtG8Ca1qFp4p1a4lggLeVcQ2nluuQGB2wBvuk9CPrSp0VOSipLX1/yHKbim7fkTfDqI21zo0b8u3hmyyfVlZtx/NxXoVc03hl5P7PuLbVdR0y6t7NbRjbCBt6DBwwkjcZBHUYp/wDwj2p/9Dhr3/fmx/8AkenVcakubmS+/wDyFC8Vax0VFVtOtpbSzSGe9uL6Rc5nuBGHbJzyEVV46cAdKs1gzUKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcj4+1rWtIfTV0a3/0adpBdXv8AZ02ofZ8AbB5ELLI24kjcDhccjnjAtvibHbRxNfbdUd7azZU0m2IEklxdS267WlkBHzRgFGUFSD8zZwO08QeGtN1+W0l1FbtZ7Tf5E1rezWsiBwAw3xOrYOBkE44FUYvAfhqJrcx6YqG3W3WPbNIMeRM00RPzckSOzEnJYk7s0AVtJ8fafqN/aWJsdRtb2d7uJoZ1jzC9ts8xXKuynO9SCpYH1FUtC+J+la3q2l2FlY34k1C1hu42nktosRyJvHyNMHfAOD5auAeM1raj4E8Pahk3FnMrm5luy8N3NC/mSgLJ8yODtYAArnacdKLPwLoFnLpjwW955emLGtnbvqFw8EPlpsQiFpCm4D+IrnPOc80AYnizxtc+GfGl4lxZ397oltoov51tEiP2fErh5mLsrEBVHyqWPHC9aSD4veGLjxQdDgleSbzZLdZhPbhWkRC5XYZfMUYUjeyBM8bq3/EfgnQfEd99r1i1uJpTALZwl5PEksQYtskRHCuuSeGBHNEngnQpLy7uDb3Si88z7Rbx306W029CjloA4iJIPJK5zz15oA4mf4xwXwWPw5pVzd3sOo2dpc24ntJv3c7OAUeO4Me75CMF+CRkY5r1eB2khjd43iZlDGNyNyEjocEjI9iRXIQ/DTwvDDPGtpekzCAGV9TunlXyGLRbJDIXTaWONpHWuvgjWGGOJC5VFCgu5diBxyxJJPuTmgB9ISFBLEADkk9qWoL+0hv7G4s7pWaC4jaKQK5QlWGDhgQRweoINAHitn8aZr/QfGN7ZPosk1ham/01I5PN/cec8X+kKr5D/KjkDbxKvvUsnxP1xr+1sbK80e+t5b97VdZ0/Sbm9hnVbbzSI4IpSzMrfKxV2AznjBr0rV/BPh7V7Gzs9Q05ZLa0tmtIEWV49kLBQUyrAkYRev8AdB61Z8ReGdM8QvZSaml15tk7SW8tteTWskbMu1iHidW5Ukde9AFLwBrcnirwZZ3+pRWwupleK7t4wdqSKxV0ZWyVPHKnkdDmulUBVCqAAOAB2qjoWj2OhaalhpUHk2yMz4Ls7MzEszMzEszEkksSSSeTV+gDjPFPhrUtSv8AUVsZbQafq9rFZ3vnMwkiRGfc0YCkPuSRlwSuMA5PIrs6K5fXPGEenatcabZaPq+sXdrAtzcpp8cbeQjZ27i7pljtbCLuY46Vcqjkkn0JUUndHUUyOKOMyGONEMjbnKjG44AyfU4AH4Vyeo/EfwtY+GX1yTWLNrcWn2yOATos8q+WZFVUZgS7KpwpxyKq6P8AE3w5qXiGfTl1XSo4Db20tpcNfxkXbzNKpjQZwWUxYOCeWxgY5go6HxRpU2q6fELKWOG9tbiO6t3lUsm9DnDAc7SMqccjOaj8KaZe6fb38uqSWz3t9dvdSLbA+WmVVVUE8nCoMk45zxVhPEWivq02lprGnNqcCl5bQXSGaNQMksmdwGDnkVhaP8Q9B1XXtYsrbUtMex0+O1P2+O+jeOSSYyjy8jgMPK6ZJO7oMc37R8vJ0J5VfmOxqqdPtTqi6iYh9sWE24kyfuFgxGOnUA1n23ivw7dXsdnba/pM13LEJ44I7yNpHjK7g4UHJUrznpjmqkfj7wdKVEXizw+5ZlRQuownLN90D5up7DvUptbFWNTxFpo1nQtQ01pTD9qgeESAZKEjAbHfB5xVLwvpeoWcmo3utTW0moX0iM4tQwiRURUVRu57Mx/3sdqW58WaJYw3M2ralY6ZBBdNaGS8vIUVnABwDvODg/dbDeoAxmXxJ4istA8PS6zcCW5tlCeWlqA7zs7BUWMZAYszKBz3qlNqPL0J5Ve5sVV1SwttV065sL+IS2lzGYpYySNykYIyOaw9J8baTqc+mxwtNHHqGmnVbeaUKqNEpUOuc8Om9dwxxnr1xzw+LelNF9oTRtbayW0t7+a52QBYIZ3ZYmZTKHO7aThVY4I4zxUptO6Kauej0VyEPjSeTxV/YJ8La6lyEWZpWez8tYS5QSki4LbcgnABbA+72rr6QBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFchq3hfVR4hv9X8Na5Bpk+o28cF0lxY/alJj3BJU+dNrgMRzuU4GVrr6KAPPdO+GFjp+h6/pVveP9n1TSI9IDtEDJEixPGX3Z+YnfuxgDIqOX4c3V7a6yNV1i1mvNSs7KzM0FgYljFtLI4IVpWJ3B1BG7que+B6NRQB5hqPwrbUWu7S41pRo8txf3ccMdmBcJLdxyo+6fedyjznIGwHhck7RUtt8Nr2XUGvNa1uzu5TLprbLfTfIj2WbSsF2mVvveb16DHA7D0qigDz27+Hk8+sXEo1eJNKm1I6sbf7FmcTmLZjzt+NnfGzdj5d2Kpz/AAoik8OPpQ1KNWbw1F4d8/7IMjYSTNjf3Jztz1/ir06igDz+TwDe23iFtc0fWbaDUftd3Oou7EzxBLhYQybRKh3AwKQ4YcEgg1teLPCo8UjRodSvZUtLK4F1PFatJA1xIqEIRIjh4wrNv4JOQvPHPTUUAeY6j8KRP4bj0ay1y5tIbe9uJbaXY0skdpcKyzWxZnJfdvchycg7eCVybmvfC7TdX8QXusNLFDefZbWHTpVtlL6fJAzsroxPIO9QUwAQuDnPHoVFAGDaaFLH4qGuXN4ks7abHYSRpDsUsrs5kGWOAS33ecepreoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rhythm strip shows a sinus (S) beat that has a short PR interval and a wide QRS complex as a result of a delta wave (d). Panel A shows an atrial premature beat (APB,*) that is blocked in the accessory pathway (AP) which has a long refractory period but is conducted antegradely through the atrioventricular node (N) and the His Purkinje system, resulting in a normal PR interval and a narrow and normal QRS complex, as seen on the rhythm strip. After normal myocardial activation, the impulse is conducted retrogradely along the AP, activating the atrium in a retrograde fashion (panel B) which results in a negative P wave. If this activation sequence repeats itself (panel C), an orthodromic atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is established.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAClAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P0tpjZX+Yfm+0SYXd15q/OZPPtMRg/Mc/N0+U1R0gH7Lfjzwc3EnzYHy1fmBEtoBL/Ec8fe+U0zrq29o/n37CW7P9tugY8L8uDnrxWXqTP8A8I4SIwW85OM/9NhWpCT9su/nGPl49OKyNQDf8I0AbgZ85PnwOf3wpPYqj/Ej6xNadpPt9oNny4bJz04p0Ly+Zd5iHD/J833vlFNnP+n2n7zAw3y+vHWktxiW8zcZy/t8vyigx+z8v1Gq8otLQrEu4uAwLdKp7pv+Eux5Y8v7GPmz/tmps4s7LF1t+dctkfNzVVsHxacXZXNoPlyP7xoZvTS970fcsM9x/Yt2WiXcPMwN3UZNTyvP9rscxpglt3PT5aoKpOj3m6/Y5MmDleOtW5wv2uw/0s8Fu6/N8tApRV38+/YsSNIWuwyKAIxt568Gs7TDOPD+nkInmbkyM8Y3Va3KJ77NzuHlrgFh8vDVR0rB8OWCi6KtuT5gwz96lccY2h849+zNMmT+2CFVdnkDJJ5+8aooZ/7P1f5I93my4GTyNoq1hf7YLfaWz5I+XcMH5jVBVVtP1YfbWXMsnO5ePlHtQEF+nfuN1Uz/AG3QMrHzMc9ePkrUtvtH2673rGE+XaRnnisfVEX7boJF82BLyCy/N8v0rTt9gv7o/bmbhflLrgcfShFVV+7j6Po/5iq7XC+H7M7I/M3R/KScdatzNc/21aqFi2+RKd3P95P/AK1ZnyN4esx/aDZzH829c9fpV2RY/wC2LY/b3/1EnG9fVPakOUbN/wDb3R9ihpIu/setjbDuNxLgZPpWmPtYFgNsPTnk8fLWTpCxm01kG+kANxJzvX0+laTJHmwH9oSDHT5154+lNbF1177/AMn2LFv5/wDad3kRfcj55/2qzNWNz/wik2Vi3ZHGT/fFXIFT+1Lv/TpM7I8jev8Ate1ZmqiM+FJv9NfqP41/vjjpQ9iaMf3sfWPRnQSm4FzDgRbcNk80im58y4ysOAfl688d6jlRPtcGbyQEbvl3rz+lIFjDXJN9JyefnX5ePpVHKlp8uz7j5ftJW1IEW/eM9cY2mq0f2n+35eIdnkDnnPWnFY/KtQL98bx829cn5T7VBGqHxBJi9kz5A+Xcvr9KTNYrR+j6PuTL9q/s254izvlx1/vmppjc+ZY4EWNx3df7jVXUJ/Ztzm8cjfJzvXj5z7U+dUMlj/psgy/GHXn5G9qAa1fz6PsTg3Hnzhli27BgjPPWs3RvtY8O22xYdwJ4Of75q4qL9puf9OkJKDguvHXnpVDRlT/hG7fdeyAZPzb15+c98U1uVFWh849H2Zpn7T/aa8RY8k5PPrUB+1fY9R3LD1fA55+WpTGn9ooftkgPlHC7l55+lVnVWtdTxeSfx8Bl4+X6UiY9Pl08yLU/tn2fSsCAf6RFnrxV1Bdf2vIcQ48hM9f7zVnakiG30n/Tpf8AXxYw68/pV1YgdYlxey/6hONy/wB5vajqaSXuff0fcb/p39mXu7yPMzJ646VamN359thYeSdx544qkY4jpt6DfylMvlt6+n0q1Msfn2ub2TOTtG9fm4+lNIzlv9/R9ippf2r+2dYyIvvR46/3Kuf6SbGDiHfvTPXGM1Q0tY/7a1kC6fdujz8y/wB36Va2xrp8GLtym9Pn3j19cUiqq99f9u9P7pcYXH2tDiPbsbPX1FVz9o+zX+RF959vXpjvUzKv2yPNy4bY3G4c8j2qqyIbPUP9KkA3Pkhhxx9KZlBbfL8xbIz/ANl6bxFnbHnr021dUXPnsT5WzaMdc5rOs0Q6XpYN1J0jx8w5+Xp0q6iD7Y4F1KW2jKZGB74xSWwVVq/n08yNjcnTyWEW/wBBnGM1FdfaP7csMCLb5UueueqU5kj/ALKbF1IU7uWGRz0zimXaKdd0/M7hvKlwMjn7ntQyofE/+3unkW4fO8+5z5ecjb19KkXz/s8ePL38Z64xUUSL513iZ8kjdyPl4/SkURiygBncJ8uG3DJ9KZi1f8PyJ/3/AJx/1fl4985rNsTcf2dc8RBvPlx1/vmtH5PtTfvm37RlMjGPXFZeniIaZebZ3K+fLubPIO80uppD4X6rp6mlMZvNtsbMFju/75PSljEv2iYnbt42/lTZQpltj5rZ3HbyOflNLEym5nUSEsu3I9OKZl0+X6mfrAuP7LQfu9/nJu9Mb60G+0fao/8AV+XtOfXNZmsLCNGj/fv5fnJh88n560W8n7XFulbzdh2jPUetI2l8C06y6eg0C58i53GMHLbMA/rSuJilpkpuDDd6dDUatAIbzErnlt+WPHHamOYDDYjzX2hhtO45PB6mgmzvt+HkeW6b8SrlLG/2fD7xQ6NO7OBbjA56E5q/L8T70yWZ/wCFe+K+vy/6MP7p6c11+lNqpstROLUsJ5No55NX5Dq3mWeRZ5JO4fNx8ppanTVgud3a69fI4/wp8RINX8aS6Je+HdZ0nUJ7f7Qn22EKHVRg9K6S/aL/AIRnmF9nnJ8pTn/XCuS1ddTT406BJi1/eWNzGG5xwobp1rpdQOq/8I7nFmT5qcfN/wA9RSu7MqFNKcLNbx6m3cOn9o2eYn3YfB2dBim28kHmX4W3lxv+ceWfm+UdKrTHVv7QswRZhcPkjd1xSwnWPMvTiy3B/lGG5+UUzH2a5d1t38xpmtxYWANpMV8xdi+UTg5qBpLceMMm2lMhsxz5R/vGnIdY+xWRxZFi65BDcfrUf/E1/wCEqxmy/wCPQc4b+8fekzeMUubVbS6kqSwHR71RZzgAyZBhPXmrlxJF9qss2svVsfuuny1QA1ddIuyWsush6N0596szjV/tVlk2Octn5W/u/WmRKKu9V16+RIZIftF7i1lyY1z+668NVLTJIf8AhHrH/RZiu5flEWT96rDDV/OvMtZbfLGPlb/a96z9JTWG8O2IjazByuMhs/e+tF9SoxXJ8S3j18mbHnxf2r/x7TFjCOfK6cms8TQ/YNWBs5yDJIceV/sirONW/tU82OPJGflb+8feqgXVRp+q4ay+/Ln5W/uj3pMmEUuq6dfMh1eWL7b4f/0Sbibj910+WtO3ng+33eLKcN8uT5PXisfVRq/2zQNz2Q/fdlb+735rVtxrH9oXWXsduF42t6fWhM0qRXs46rZ9X/N6FJJIToFmPsM/VOPJ96vSyw/21an7HNnyJefJ90rP26uugWgL2ecx4O1s9eO9XpV1b+2LU77LAhk42t6p7/ShMU0rvVfa6vsVNMkh+y6x/oku0TScGHGeKuNPDmwP2G4OOmIOny1m6b/azWms7WtA3nSDlW64+taKrqxFhmSzyBz8jf3frQnoOrFKb1X3vsT20sTancj7JKuUj5MXH8VZertCPCdwPssnBHAi77xzV+Aap/a13+8tNuyPA2t/te9ZWsJqn/CJzZktuozhTnG8e9DYqMV7WOq3j1ZvvNG15ADazZIb5jFwKXzIg1xm1lPPP7rrxUEqap9sg/fWmz5sjYf8aAmq5ux59qSfufIeOPrVXObljZarbu+/oK80LRWZ+xTYMg+XyeR8p5xUUckQ8QyD7NKD5A58rjrSGLVhDZAzWu8ON3yHptOe9RImpf8ACRy/vrfZ9nH8B/vfWk2axjG0veWz6vv6FhZYv7OuR9llI8yXjyuvzmpppIhJY/6LIfn4/d/d+RqqxxamNOuR51vkySlfkPHzn3qSSLU/MsMz2/Dnd8h5+Rvenclxjd+8uvV9vQmDx/abnFrL9wc+X168VQ0R4v8AhG7bNpIwBPyeXk/fNXgmo+fcbprcqUG0bD1596y9Fi1M+HLdUmt9+TyUP98+9F9Sopezeq3j1fZmz5kZv0H2eTPlnDeXwOelVi0Zs9TxbuD8/VOvy04x6j/aSET2+wRHcNh5OfrVd49R+yalmeDB34Gw8fL9aLkRitNV06vv6DdRMRt9J/0aT/XxY/d9PrV5Cg1iX9y3+oTnZ/tNWXqUWo/ZdJxcQ7hPFk7D/jV2OLUP7XlJuIMeQv8AyzP95velcuUVyfEuvfv6CM0f9mXv+iSdZPlMfXirUpjNxa4tn4J58v7vFUHg1UadeA3dvv8An58s+n1qaeHVfPtcXUGATu/de31p3JcY3+Jder7egzTDH/bWs/uGHMfOzr8tWd6DT4D9lkA3qPL2cjnrWbp0WonWtXxcwjmP/ln/ALP1q0ltqv2KISXcXmB1PEXbP1oTKqxjzK8l9nv29DRYqb2P9033G+bb05FVWK/YtSxCThn+UDluKJYNRN5GUuogmxs5j9x71TNvqZtdRAvIuXfb+66cfWhsyhCOnvLp37+hZsmU6VpR8huRHxj7vy9a0Vx9pceUQQo+fHB9qxbC31D+zNNzex4Cxk/uu2361fEGo/aGJvIzFt4Hlc5oWwVox5n7y69+/oOkI/s1j9mZf+meOTz1qK7bGv6ePKLfupvmHQcpUc9vqf8AZ7L9rjMvr5fvUNzBfnW7DF3Hjypc/uvdKTHTjG795fa79vQ1Im/f3X7o8Ef8C4pqSH7FAwt2JO0bOPl96rpBf+bc4vE5I25iHHFNW21MWsSi+jDDbuPk9qZHJH+ZdO/b0NDeftRXyTjbnzOMfSs/Tm3afdfuCuJ5Rt4+b5zzU32a+80n7au3A/5YiqFhbagLC6H21d5mk25iGPvml1HGMeV+8t138/I15mImth5ecsef7vymkiZvtNx+6wPl+bI+biqcttf+dbH7euAxz+5H9006K2vhcTk3ykHGP3I9KZPJG3xLbz7+hBq0rrpKk2xJMyjZuHHz1os8n2hP9Hz8p+fcOPasbU7TUf7NUG/Ut5q5/cj+/WgbXUPPQjUB5YU5HkjOaDSUYci95bvv5eRKJJDDc/6KVA3fxD5qY8k3lWh+ynO4fLvHy8Goja3/AJM+dQHO7b+5HFRyWeo7LUDUfmDDd+5HoaCVGHdf+TdippawfY9RzeyhftEnzeb0q/LHCZLMC9lxkkHzevymqOlSr9k1EGxnI8+Tjy15/Wr7yr5loBZTjkgZRePlPvQjarfnfz7djjNfjhPxV8Ln7VJkpdLxJ0Hkg10F+kQ8OH/TJMeanzebz/rRXPeKZlT4l+EWa1mUebcgHYvzEwdOtdFfyg+HSPsU2PNT5di/89R2zStuaQvzQ9Y9vM0JkhN/aYvJCcNgeb14pIY7fzrz/Tpfv8/vunyinTzAX9oBZTdG52Lxx9aIZV867/0Cbl+fkXn5R71Rz68vy8u5WSO3FhaD7fLjeuGM3J5qEJB/wlGPt02fsg/5bcfeNWElT7DaZ0+c4cYHlrxz9ah85P8AhKgPsUufsgP3F/vn3pM2jf3vR9iXy7cabdYvpSCJM5mzjrUtwkIurL/TJuS2D5vX5aY0q/2Zd4sZhgP1ReevvU9w6i5sv9DlPLY+QfL8v1pmbbv9/bsMdYPOu/8ATJOIhn970+9WbpYth4dsgb+ZQWXkTYP3q03lUz3i/Ypv9UvOxefve9ZelTIvhqwzYyt8yj7in+L60uppC/J849uzNPZB/amDey7vKHHm9eTVKOGA2GrD7bNjzJMnzv8AZFaQK/2r/wAej8w/e2jjk+9Uo3X7Bq3+iSf6yTjaOflHvQRCT/Lt3KWrRQC50IfbJiTPwfO5+7V+1jtv7Tu9uoTlgEyPO4FV9VdftWhYs3/13XaPl+X61ftX/wCJneA2MijC4baMEfnQtzScn7Nej7fzGakMB0C0Y3s+3Kc+b71flii/tm2H2ybcYZeBL7pVRJS3hy0P2OXO5Pl2jn5uvWtGVh/bFri3b/Uy/NgccpSRM2+Z/wDb3bsZGkRQNa6z/pkxX7RJn977VoNHCV07ddzD0Pm9flqrpD4h1oi0cYuJMDaPm4q+zhRp/wDorEHtx8vy0LYdaT9o/wDgfyhBFF/al2RcybvLjBHmf71ZOrJD/wAIfPm4kZcjrJzneK1oJX/te9AtXwEi+bjn71Z2qsw8Hzt9nIfj5eP74olswo3VSPrDsa1wkf2+2Bmk3YbAD0kCQ+belZ5TyN/z5x8vb0p11MYrqF5Igsaq7NIzABAB3NJZ3K3CXEsCJJGcFGRgyyDHUEVRy3fL8v1GusDW9lmaTy967G38k4OMmoUEf/CUSDzG8z7MPl3dt3pVovIILQi2BJcApn7vB5qshceJnHkjBth8+f8Aa6UmXC/vej6ruKEiTS7s+bJs8yXcd3Q7zUsqxCTTcyP9/wCT5uv7tv6UZkOm3P7kZ3yALnr8x5p1wziXTgIlPzn+L7v7tvagV3d/P8gXyxd3eJH3BBuG7pwazdF8g+FrYvK4iycNuwT+8NagaQ3FwPIX7g53/e6+1ZmiSTf8I1bkWwJyfk3dPnPtR1Ljf2fzj1XZmiyxDV4iZG8wwkKM8EZqNljNpqgVmOS+/J6fLU7tJ/aKAQgjyiS27pz06VCzym01DMSjBfA3fe+X6UGcb6fLr5lLVUh+y6NudwouItvzdfrWggX+3JTk7/s6cdsbmqlqbTfZtLPkKT9oi439P0q+hf8AtWXMY/1C87v9puOlIud/Z/f180VZRbjR78bm8r95k5Oc4qxcfZxLZ7iQ275OTzx3qKSSb+zL4+Qm4eZ8u/rx9KsTSTiS3H2dGyeT5n3ePpVEu/59V2M3SvIXXtb253Zi3df7tWT9k/s2HBbyQ64POc5qDTWmGt6wRCvWL+Pr8v0q0Zbj7HETaoG3r8vm+/0pI0q351/271X8pM/2f7ZGxH7zY2OD0yKpt9lNpqQb7u99/X0qa81AWl7bJcG3i87KRmScLvbj5QCOTUZkuBa3+LaMgM//AC168fSgzgnp8uq7kNp9kOlaUSOAI9vB67avqLT7UxA/e7Rnr0qpYzXK6VppW3jOUjBHm9Bt+lXhLc+aV+zJtx97zf06UJaBVvzP59V3KUqWP9mt8p8vv1znNR3gtP7d08uvzeVLjg/7FWpprtrNm+yxhv7vne/0qG5e6/texIt4z+7lz+96fc9qTLpt33/m6rsSwi08+6AUdRu4PpQFsfscOV/djbt4NPgkuvPuSbeMHIx+968fSnRyXQtoiLaMtgZXzen6UzN3vv26rsGLNbk8fvdvoelZlktiNPvPl+Xz5N3B/vmtfzLnzSPs8e3H3vN/pis+xkuvsNzm1jz50mB53X5z7UdSoN8r17dUWJ1sxNa5UZ3Hbwf7pojSy+0zkIN+Bk4PpUkkl15kOLaPG45Pm9OD7UqSXP2iYfZ02jGD5vXj6UyLu2/Tuu5kasLAaSpCfJ5y4GD/AH60HTT/ALTEDGN5U7eD0qtqsl2dMBa1jV/NX5RLn+P6VoNJd+emLaLbg5bzeR+lFjWTfIter+0vIqrBp5hudsfdt2Qaa8WnhLUCP5d4xwfQ1deS6CSYt4+Acfvev6VznjXxanhSw0y71K1ylzeRWoCS/dZ+B26UnoRGUm9//Jl2LulC9FpqJMkJP2iTHymtKUXRltCHhHPPynn5TWDpWn2Is9S/0q78sTvu/wBKk/xq/Lp1iZLLN1edfk/0uT+6fehXOisoc7/+R8vU5bxtHcf8J74OkMkIUX0gAwc5MNdLfi6Hh0/PDv8ANTnBx/rhXG+PLCyj8X+E5PtF0ZP7UWM5uX4DR8c54ro9Q0+xHhok3FyU85ety5/5ajtmp1sy6aheGvWPT18zoLhbr7daHfFtw2flPXFOhF15t388Odw2/KePlFUJ9NsxqFmPtF1uw23/AEp+mPrSQ6bYNLe/6Td/ew/+lSf3R71Wpz2hyrXp/L5+pMgvPsFn+8h3eYuTtPPNeZ2Oo3j/ALT+oWTXA8pNET93zt6hunrzXcf2bpn9nWG6e52+YoX/AEl/X614zpkFi/7VN+vmzGEweQp85slhChI3ZzjPapbehs6cXzNX6/Z/4J73suxpV3mSIsfMIO08DmrMwn+1WWWj6tu4PPy1hx6dpg0m9KyXBUGTOZn68+9WpbDThcWADzFWLbczOf4frTuyJQjd79fs+XqXytx9qvfnjwYl2jB4+9WVpsV23hWyRZYlfcvJXtuqRtM037Tfj97xEu796/8Ate9Z2m6XpjeFbJpBJ5ZZed7dd1J3uawUFHd7x+z5PzOnAm/tPJZNvkjIx7mqaCb7Bq2HTd5kuDjp8oqAaPpi6rjyn3mLP329T71WTStOGn6sdkhVZJM5duDtHvT1Moxp930+yu/qW9UEn2jQvnXiYbuOvymr1qbj+0rsM6FAEwAvTg1iajpunLPof7twWmG0bjz8tXYdF0ptRutsTGXC7xvbH86NRzVP2au3s+i/m9RqrP8A8I3ZgSoJNyfNt4xmr8wm/tm1+dAvky5G3rylc82j6T/wj1s3lyeXuTJ3N1zzVqbRtK/tm1Tyn5glON74PKe/1palyjTu9X9r7K7eo7SBdG11vEybxcSbTt6cVoLDcsmnEzLlcFvl6/LXP6Vpukraa0VtztWZxyWPatJ9N0t4dOZ4SAQMfe5+WhXsVWUOd2v/AOAr+X1NO3SX+17wmQbTHHgbf96srV0mPhC4BmG7I5C9vMFPttL0kavdgW2W8uM4IY/3qzdVstKPhCdhbKFBGDtOc7xQ9hUYx9rG194fZX+ZF8YpLi38Ca1LDPs/0KVMAddwC/1rK/Z5eeb4SaK8k2f9HVFGPu4GKX4x6bpP/CJyRtbhHleOJSoI+9Kg/wAay/gBp+mj4dvDNbiRoLmaFiyEnCsRxR1M1CPsd39y7+p6pIkohtB5/wA4cZbH3uDVdUf/AISRz5vH2YfLj/aqi+naI1pak2SbC6gfuznODUK6ZpP/AAkjqbKIj7MODHkdabFGELS1ez+yu/qa4jl/sy5HnfMXkwdvT5zUlwj+bp3708SHPHX921ZC6bo4066/0KIjfJnMX+2elPl07RhJp/8AoMQ+c7f3XX5G60C5I3er6/ZXb1NYJJ9quT5pwUGAB061l6EkzeF7cCch8t823/poaP7O0YX1yDYw52An91x36Vm6NpujHwxCz2MTAlufK+b/AFh70dTSMIez3e8fsrs/M6rY/wBsU+aeIyCMdeetVikgs9QzKTkvg46fLVM6do/9owr9ggz5R2/ueOv0qL+zdH+z6gRYQ9Xz+6/2e1PUxjCK6vp0Xf1LGpRy/Z9LxMeJ4snb1q6qv/a8n7w48hOMf7TVg6hp+jiDS9thAA08YH7nqPfiryaZpP8AbEiiwt8+Qp/1Ix95valqXKMeTd9ei7+pcaN/7OvVMxJPmfNjpxUtxFKZbbFwQFbkbR83FZLaXpDaXesNPg2DzP8Allz07VJcaboqyWwOnwctwBD7d+KepPLG+76/ZXb1JNMgmGt6wzTHaxj2/L/s1aEcps4R9pJO9fm2j16Vh6fZaQ2sarE1jAY4zGVUwjC5XnHHfFSDTtBFhEf7OgCeYv8Ayw5+9QrmtSEXJXv9n7K7ep5l+0xLcQX/AIEaCYgrqyNwBx0Gf1r2DyZfsmoA3J5Zudo4+UV4f+0Rp+mHUPDqW1jEnls077IQMgOg549zXrNtpmhSabeMumW4GCf9QP7o6cVOuooxjyLV/wDgK7+pqWkUh0rSv9JIwsZztHPy9K0PLl88/wCkHG37u0fnXO2mlaIdM0xjplsSRHz5Aznb34rQXTNFNyyjTbbdtyT5A/wqlexFWMLvV9fsrv6lp4pfsDD7Ux/2to9aZdJL/a9iv2gjMcv8I5+5VFtM0IWLFdMt9menkDPX6VHdaXow1mwX+zrbmOUgCAY/h9vrQ7hCML7v7X2V29TZiik+0XJ+0NyRxtHHFNWKQWkIF0R93DbRzVGLS9HNxdf8S224xn9wOePpSLpWjfYoGbTbbbhcfuBkfpT1ItC+76fZXb1NYRS+dn7ScY+5tH51m2Ucg067H2kk+fJ82Bx85p39n6R9r2f2db79u7d5A/wrP07T9JaxvD/Z8OBPIDmHn71LW5UIx5Xq+n2V5+ZuyxuJLbM5yGPYfN8ppIkf7XPm4Jxt+XA44qnNpuk+dbA6fbksx2/uRx8p9qItN0r7VcAWFvuAGT5I54+lPUztG2727Lv6jdWUnSh/pmB5q/Pgc/PV90YSxE3eOD8uB83vWHqOn6QNJVxp8IQyrgCEA/frTfTtL8+INYQFsHafJGAPypalyUVFavd9F5eZMqsY7g/bNwy2eB8teI/tS3jW/h3wwiXW8/2lHLjjnZzmvZV07S/JuCthAPvbv3I5/SvDv2lrCye00OK0s44ykU87BY8HaqUpXsVSjGU7K/3Lse1aS7C11E/ZGJ+0SfLlef1rQld/MsyLVsk88r8nyn3qnpUcq2upASgM08hU4+7V6VZPOsv3o4J3cfe+U1RnVa9o/n37HE/EdnGpeG3W2ZlTXLX5ht7gjFdDqTsPDZItmJ81Pkyv/PYe9c58WpXsdKh1SS4WO1sNTs7qUkcIit8zH86121G11DwiLiw1S2uYmlUrPEwZSPOFS3ua0rXh6x7m7cO39oWf+jtjD5OV44+tOtndpLzNqykPxkr83yj3rzbxj8R54vFMWj+CtPfxHqltGzXEcDgRwk8AO/TPtXMeHvjXfnXGi8U6JLoWlz3DWbX05+WG5VBlD7e9HMZqk3BPTbz7nsnmSfYLIiy5Mi5Usvy814JoVxL/AMNC/aTbjM2o3kIwR/AAvX/gNe6L5sulaZKl4pR5EbcAMMCeMV4A1r4gjvdP8V+GrL+17tNQvb0W6sF3RPPJzn6DNKT2OujFWnttLufQxkmOj3n+jKMeZxuGD19qnuHm+12H+jr1b+P7vy/SuW8C68fFPw/OrrJJA1wJd0T43RMCQVP4iuqnRvtVgPtB6tnp83y07nLJJSe3Xv2E3zm8vgYI8eUmDv6/e9qz9He4XwzZEW6Egj5d/wDtdelXwjfbL3/ST/ql44+X71cZq3jHQ/C/g+2k1bWo45htKwRsrSyHd91UHJpN2ZcUnG2m8e/ZncF5xqu0QoU8kZbf05PtVdGmFjqZMaE75MAP1+Ue1eV3njzx9f3bX3hrwVcNp6RBhHfSrFNMuT8yr/SruhfF7wtd6DfPq2rLo+ol5BJY3nyzRNgDbjHrRzEqnZLbp3PQNWeQXGiDykJM4yd3T5T7VpQPMb25UxIAAuG39f0rjLjxl4Zvv7BntvEmnSJ5oO4Tpz8p6+lacHirw+t/csfEunkEL8puEwOvvTTQppezXo+/8xf8y5Og2rCCPflMLv8Af6VdmM39q2uI4yfJlz859U9q5MeKdAGg2o/4SawyGT5vPTPX61cm8WeHRq1sT4m07Hkyf8vMeOqe9K6HJK7/AO3u/Yv6Z9oWDWMQxbjPIceYeePpVwPd+Xp5FvCTxn96fl+X/drl9F8TaJcDVYovEdi8slw4jCzpk8cYGeateKfEem+GNBtNS1PVGWCPaAsZDPKxHCqO5NNNWLqJOb2/HsdFC91/aVyPJh27EwfNP+1/s1kas91/wiM+YIu3AlJ/jH+zXleq/EH4iRTPqWmeDJ3sLgxxwwSuBOAc7WZR90Gt/wAIeN7Txb4DvImuja65aYS9sZCBJC3mDt3X3pNl0qaVSG28e5r/ABde8a00KBIYiZtUgXHmE5w4bH3faoPgp9rh0PX4PJiDQ6zdpgyEYO/p92rnxEjebxJ4LtVuG+fUTIcY4Cxsc/rXHWmseIPAHjLVbXWbAf8ACLarqzvDqUcqlonm5XevYE0dbmS5XSUVa9vPuexb7zybYmCAybhkeafQ/wCzUCNc/wBvv+6hx9nH/LQ/3v8Adp4hc2toPtj53D5xjng1Esbf8JC/+kt/x7j5eP71UyIqPvbbPv3JQ93/AGfOfJh3b5MDzDz8x/2adM935lhmGH/WHP70/wBxv9mq91NDa6Rdy3GoLFEpkJkdlAX5j3rzjxJ8TUu9VsdF+H4fxFrQJZjEwFvENhGXk6Z5zik2gjFSb0XXv2PTxJe/bLgLBAQEXH74+/8As1Q0KW7/AOEahZYYTJluPNIH+sP+zXlN5qHxb0G5Gq6hHYataAj7Vp2nqDMiHOCuepFS+GfjL4Rfw0kGo6vc6XfxOyzW1xCQ6HeT6YPWknrqbezjyWVt49+zPZGe6+3RjyYdpjOT5p4Of92ome6Ntf7ooRjdjEh5+X/drz5vjF4F+3xN/wAJQu0RkH92cfjxWpa/EPwfdWV28Xi7TWWQMVDXCKR8voeaq6MFC1tO3fudLqLXJt9N/dQ58+Mn96f/AImrqNN/akmY4wPJXkOf7ze1cVqXjvwm1vpoXxbpZKzxk4uUPHqeaux+PvCJ1Z2HivSSDCox9qjwfmb3pXQ5L3Nu/fujo5HujY3mIot3z4HmH0/3alnkvBJBiCDBb5v3x44/3a5NvHXhP+z7xV8W6WWbfg/akz0+tY3iv4jQy3umaV4EuLfX9cuWJWOCZTFEoHLyMOgp3QlG7tZde/Y7fTmuhrmrHyYcHyv+Wp/un/ZqZXvvsMP7i33714844xu/3a8O/wCEn+LGgXmv3GpaJp98lmkc9zJbyYBj5+VB3IGa9S8HeJNP8U+DrHVNO1LdFI67/mG6Jt3KN6EUJ9zapBcyen2e/Y4v4vzXNx4jmhEEDfZNGecjzCcZnTn7v+zXpemz3c2iyyeTCGZMgeaf7g/2a831XTpvE3xK8Y2Vpe4ZNGjskY42+YxL4P5rT/hn4o1GO+1vwb4xuLa116xiV4PKcbbiIp95c9SMDIqbi5VypadO/c9Ks5LsaVpeIockRg/vT02/7taINz53McPl44IkOc/981nWS50jSf37EERYbjn5a0lXFyT57E7fucfnVLYwrW5np379yFmuzbHMUPmZ/wCehxjP0qC6M/8AbVjtSPHlS5y5/wBj2oup4LbTXe4v1jQEgyO4GOema4PxL8WPBula7Zh9cW6liSRGisl84liVwDt4zwaG0OnH3tF/N37HosTTma4zHGCCNvznnj6URtci2i+SLfhc/Of8K888P/GLwRqt5cxf24LGdmwI79TAQQMcbuK7y2uLefTbdob5HQhCsiuDuzjH50XRDjbddu/YtFrj7QQI4vK29d5zn8qo6e901pdZSLcJ5AvznpuPtWgADctiU7tv3M/rWVpgjWwvR9pZh9okyc/d+Y0dRwtyvTt3NGZpvOtvkjwWO75z/dPtSxGb7TOGRNvGCGOen0ps5UTWpMuMMe/3vlNEUkZurg+eOi8buBxQRbTbp+pT1Q3LaVnbH5nmrn5jj749q0yZPMQBV2EHdzzn2rhfiB4z0Lwr4bV9S1DfK8gMMER3yzkPnCgV5/qvxl8UR6pbSweBL+LT0ja5kM0nzGDu2B0YelJyRs6Upxsl1f6HvDGXypchA3O3n8s14v8AGxLm81eG3McbmLRbuVvmOASuK9L8KeJNI8T6CdT0a/E9tOCx+bmM45BHYiuN1nTLbxB421K1jvjlNKFqGLZGZM9aHqtCsOuSd5Lby8jrNO1Gxa01LeszIZn3fu2zir0uo2O6x3RzYB/d/u24+U0ukG5EF+RFDv8AtD4G44P6VelNx5lr+7izn5vmPHynpxTKqyhzvT8fL0Mm5fSdRlv7a/tPtMUqqJI5oC6suOhBGK8v1f4ZfD19IluodKurV3lXcLeWaNT+8APyg7entXpmqeK9I0TVJrfWdV0uwkcK0a3FyI2fj0NZHinxZpGleHIv7R1PS7WSd0kiSa5C7180HIz1HepdrM0oNc8VZ2vHr/wB3h/SvC3hdrGz0DTPscOHJ2ROS3HVmPLH3OadrNn4b12w1ex1ax+02szfMrwFsHYPmHHBHY10c008l9p7wpA8TqzBw5PG3jHFFu1402oAxWw+cD755+RfamSpx5b67fzf3vQ+dNR8NeMfDXhyGLwl4ik1OxMirb2V5ZEvGCcYD+g616p4NstL8PPpGlGCWV7TSo4Xb7OTvcfebGO5zXWj7b/Z1hiK2JEqfxn1+lITe/8ACVj91bf8enXe398+1TY6faxtJLtL7X/APGdS8I63YP4ivPBuufYbG9nef7Bcab5io3fax+6D7Cp5NB8fXQ05LrxfBbs4IPkaIuY+OcEjk17Ju1D+y7vdFaD/AFmMO3Tn2qxO179qs/kts5bPzt/d+lPlIdZJ7d/teXoeD2fwu1H7bqsd5498RyQyqDJ5dpsZ+vGSTt4HbFdX4K8GeCdB8P2s8Hh/zr1mUyXVzbtNIzbuu5s4/wCA4Femg332u6/d22PLXHzt/te1UdGN8PDlpiO2LDHV2xjd9KFGz0D2sXG77x+15PyF+2ad/aQ/0GTd5QAP2Y8cn2rFm03wzdQ6pLc+H7WWVpJMvJp6sx4HcrXWKbz+0PmSDy/LGSHOep9qrA3f2XUcLAfnfHzH0+lVYwjOP5faOC1fwf4Ee60gnwpZKXmGdtgFDDb3wOasxeCPh+b24B8I2ZIC8fYeB9OK63VWuhPo2Y4M+eM/OePlPtV+I3v2yfMdvtwuDvbJ6+1Kxc5x5F6P7Xmebx+CfAX9hQOvhO0OWTLGy5PPPNWZfBPgD+1bdf8AhELPBikyPsHBOUxxj6/nXZg339kWwEdtkFP42x1+lWJmvP7VtsJb48mTq7eqe1Fgc43f/b32vI8qX4dfDu6i1c3HhVSRKwUxRSIUA6AbSMVa0f4d/D3SLvS7+z8My/aUIZWlE0oBx12uxGfwrvNKe+K6vlLUsLh8fO2On0q8jXhisTst8kAn52/u/ShIqpKKk9P/ACby9ChFd6b/AGnc/wCgyZ8uMf8AHqf9r2ryn4neA9G1/TE1vSBeaLrdscC4trYKso38+YABu+pNe0w/a/7QuCUg27Ex85z39qyNZ+2f8IjcgrBnHUMT/GPalJaDoTi6kV5x+0eZeBPCuraJ8QmufEN/d61pkUBFlJcWoDrI33zgD2/WvQfE+kaP4n0PV9Lv7OZYLhQpeODbIpA4ZTjgiulmN19tt/kg24bPzHPT6UK115t1tWDII25c+nfimo20MJ1VKzt07+Z4Y3w61/T4LR9I8c60FLhRHdaekwRccdepFJL8M7y414W91418TSRtb5naOFUZ8nouB8or3KN737NBlLffkZ+c4/lUC/af+Ejc7Ytv2YfxHP3vpS5EbRxHxej6nk1l8IPBMVvNcX9rrupeU74ivbiRkJDcHAxk/WvQLKz0LSU0yLStBjtIt5O2CzVP+WbdcDmt9jcnT7jKwht0mPmOMbj7UsxufN0/iL/WfN8x/wCebe1Oxk6qbb9evkZ0VxYG/uv+JdJ9xSf9HHPWsTS7fRn8ORvLoaSszMSTaKx/1h74rr4zcfbrj5YsbF2/MffrxWdoy3Q8OxoghEgZ/wCI4/1h9qLO5aqLk+cevkylJaaG9/CraBEd0bdbJOn5Vj/8Ix4PePUv+KM07cC3zf2ZF/d7ccV3DC4N7CQItgQ7uTnPtxURM5t9Q3CPq23k/wB3vTszKNSOmnbr5nB6l4V8HLaaXt8G6cu6ePONNiBPqDxzWhH4T8HDV3UeDdLH7hSB/ZkWB8zdttdFqf2j7NpefK3faIt2CcVfTf8A2rJ93Z5K8Z5zuakVOceTbv180cOfCfg86Vet/wAIZpowZMf8S2LI49ccVrWOk+HdImhfS/DNrZySEAvb2KRnp3IAzW4fO/s6+yY/M/ebeuOnercvm7oNuzG75859O1MiVRX279fI5yxubU61q27TpTjywf3AP8JrybxH8JNI1C5vNR0yfXtKhvWBmsrPEcLvn72O34V7ZY+cNd1X/VlSIivJz0PWi4+3DTUw0HneYuDzj71Jq6N/apTWn8vXyPO/g/4YbwPoFtp2pWdxe6lK0k1xcGMNliQAMnnAUCn/ABC8F6R40sZZZbG/sNTspy8N/aRqkygAZXd3B969LcXP2yH54guxtwweeR0qALcfZdRAePJZ9pweOO9FiFWi2nbt1fc8Ls/h94u01NNl0HxprKW0pTKXtpHceX8vBXdx+gqa98P/ABdlvYJV8RW/2m1K7QlgiJOueTJjv7DivbNPW4/snS90ke7bHu+Xtt7Vo4l88ncvlbeBjnNJRCriUpNcqe/V9zw+w+HF1rOy/wDiTeXviEW6sIbBbZLeCJ2PLYQgsfQmu+sNH0TQdS02DR/DMVpGIpMeTbIp/g5J6k+5NdZKk/2OQeYhlzw23jrVa6Wb+27DbIu3y5dwK9fuUWsKNZSk3b+bq+xi6vomia+LyHWPDcN4hAGZrdGYfL2PUH3FeZv8EtAWyhfTbnxbpw+QtFb3gCkg8Ngg9M17jCsonudzrgkbfl6cUxFuPskX75A2Fydn0qrXM41lF6eXV9jxyT4aaxbagk2jeMPF8F1GAVkunjuExnoUOAfxqhF4B8WalDcSaj421/yo53BjtLaK33/NySV/wr3fZP55bzV8vbjbs5z9c1Qs1uPsd1mVN3nSY+Tp8xqeVGkcQnHZdO55VcfCt3Nuknijx46OSGBv06bT/s8VHa/CRImntoPEnjpIAoAX7enQjoTivZpEm8yD96oAb5vl68GlRZfPmO9QvGPl9qfKiPrOmy28+55H4b+G+heEI31G2stW1C+dkRZdQlWYxDfzs6bc969PkvJDPEG0u4JII3fLgD060mpJcDSyGkTf5i87P9sVfdJ/NQrKoQA7hs6n86drDnVjKKulu+r8jx2++Gt9Ya1qmq+BdS1Hw0b0N9pto7eKeKZuTkK5wvXtWp8JNI8Q6FpE114utpbzXL26zJKoQfu1BCcDAHFemqlwFfdOpJzt+TGP1prpc4hAnTdu+Y7OvHbmlYj26as0vxMzS1X7PqAW8OTO/wA24cVekC77XN3gg/3h83yms7Szbta6j/oh2id8jyutXZRbiS0BtCeeP3XT5TVIqqvff/A7HgP7TFrbzeMvAzSMjl9RWNi204X5ePpUv7SFlaSP8Pg0iSbtZ8kk7T8hccfT9Kh/aVkjfxf4QW3sbqX7JepcXBhtmYLH8vXA9ulM/aD1OymXwM9nZXDx2+pC9mKWjYEO8deP0qO5rZuKt5fke+3AiXULALebVAcBQy9NtR24Qy6l/wATEnL8YdePkFRtNZXF5pssdk+2RGdSbfHBX6UWhtDPqX/EvYfvO9v1+Qe1MlJqPXbsv5iIRJ/Z1h/xM3GJE/jXnmnBEHisH7cx/wBE6F1/vGmBrP8AsuwJsGI8xMD7P05+lKGtj4rUCyYf6J1MGP4j7UGuvvb7S6ImEaf2Tej+0HOTJzvXjrVqdENxZYvX4Lc715+WqmbX+yLwiyIH7zjyev6VamNuLmxxaEZLYHldPlpmMr3+/t2FVUN5d/6a3+rXjevH3qz9JVB4btcXzgZHO9f73Sry/Z/tl5i0IxEuf3XX71UNI+zjw1af6GcEj5RFn+KjqUvg+ce3ZmptT+0+bt8+V93cOeTVdIwbLU8XTn55Odw44FWT5P8AaQBtiT5XDeX05qshiFhqhEBxvkyoTr8opmUb/l27kOqRr52ik3bcTjALD5vlNaESoL2cm8Y/Kvy7hx1rP1QRebon+j9Z1x8n3flNaEYtzezr9l+YKuW8vr1o6lTfuL0fb+YoCNTotsBfMcMnzb19aszKh1e2/wBMYEQy8bl9UqsnkLotsRZnG5Pl8r3qzKIP7Yth9m58mXnyvdKQ38T/AO3u3YoaUibNYU3zDNw/zb144q6yI0em4vGGMfxD5vlqlpX2fZrLfYzxcP8AL5XXirgEIh00m1PO3pH935aFsXVvzv8A4H8pPCE/tO5/0pi2xPl3Dj71ZOrIn/CJXG66cr67h/fFa0JhOqXS/ZiCI0y/l9evFZGsmP8A4Q65ItTn+7s/2xzSlsKhf2kPWPY2p1X7dbf6Q2cNhcjnimRiP7Rf/wClNyV3fMPl+WlnMf8AaFn+4PIfnZ04psXl/atQ/wBGPBXnYPm+WqOdfD8vLuRlY/sVmFvH2+YuG3DnrxTVCf8ACTN+/bf9m+7kf3qkV1FlaEWbHLL8uwcdeajVgfFJXyD/AMe338D+9SZor+96PsTbUGnXX+kMV3yZbI+X5jxUkqr5un5mYnedvI+b921MDD7BdYgPDycYHzfMeafO2JdN/ddXPYfJ+7agz1u/n+Q6JVF9ckSsTsXIz0rM0d4x4aib7QVUO/z56/vGrUjP+nXP7o/cXnA+brWXobAeFom8jf8AM/yYH/PRqOpcfg+cfyZpOV/tODM5BMbYTP3veoQqeTqWJixJbcCfu/LVpm/06EGA8oTv4+X2qEn/AEfUT5OMFv8Agfy0zOL2+X5lDVhGbTSMXDbRcRYIb71XwE/tuXLtv+zp8ue25uapatIVs9KIt2/4+Ivl44q6jt/bUg8o/wDHunzcf3m4qTWV/Z/f27or/uV0m/xM2zMgLE9OKuzFPMtf3hzu+UZ+9xVRmb+ytQJgIP7z5OOeKvSyFfI/clixx2+XimjOe/zfbsjPsJIv7c1YCUl8Rbh6fKabMtrJpkYNzJ5fmL8249d1GmyE67q48hgQIucjn5TUwlZdPiItH++PkyP71CNJaTVv7vVdh8gt/t8JaVw4RsDceeRUHmWxt9Q/et9593zHjirrSSfbY/8AR2I2N82RxyPeqxmkFtf4tm4Z/wCJeeOvWhkRvZfLqu5HYvbnStMzIQMR45PJ21eBg+2Nh283ZyuTjFUrOaQaVpeLdjlYx1HHy9etXzJJ5x/0dsbfvZH5daFsKr8T+fVdyrI1q1lIBMxj3ctubg5qC9e3GuacXkYHy5cfMefuVdkkk+ysRasDn7uV9frVa6kl/tqxxbsR5cueV4+570MdPf8A8C6rsSxPb+fdHzG6jdyeOKjEtn/Z8O6VggCYO5varEMspnuM27DBGDuXnj601JZfsUR+zHOF+Xcvt70yf+B1XYcHtftRYSN5u3pubpWdYNaCzvcTNt8+TcdzcfNWr50vmlfsz4xnduX8utUdPllNtdf6K2fPk+XcvPzfWkVD4X8uqLDyWxa3/eN975OTz8ppEa2+0zfvG3cZG5uOKklll82D/R25Y5O4cfKfeljll8+UG3bbxg7hzx9aZn0+XddzJ1T7GdH4lfb5q4O5v+elaTvaGeEmR9+DtG5ueKq6pLIdKYm2YHzF43L/AHx71feWXzYgLdiDnJ3Djj60dTWT91er6rsiNRakTAO/zZ3fM1Ru1pstx5j7Q2F+ZueKsmWXY+bdsjOBuHP61GZpiISbVwS3I3LxwfegyTf9NGNpi6yYb4IdPDGd8ZD9atyf22Hth/xLs554f0NM0xIPJv8A/TGCmd8t5g4q3KIQ9sDesOeP3i88Gix1VJ++9F93kVYl1k3dz/yDcfL1D+lZWpjWT4eO8aaR5qcAP/z1Fb0Ih+13RF6wY7cjzBxx1rG1Rbf/AIRsg6g2BKnPmr/z2FS1ozShP95HRbx6Fy4Gt/2hZ5Om/wAfZ/T60lv/AG6Zb75tNzv/ALr/ANxcd6muBB/aVkRfsSA/Hmr/AHaS2EHnaj/p7n5xn96OPkFFiOb3dlt2/vFBF106fYfvdOH7xc/I/PP1p7DWP+EnT95YA/Zem1v731qWMWv9macDfMFEi7T5g55p+YB4tT/SSXNpwN4/vGixrzu8vdW0ugwJrI0263zWP/LTGEbpzU08esm4sv39luDNn5G5+X60Frb+yL7bduVzIGO/oasz+R9o08GZjydh3dflosYubv8ACuvTyKix6z9uu/39ljy0x+7b/a96p6RHq58PWpjntByDyh6bq10aEX97++bPlJu+bp96qGkC3/4Re1zMwjyMNk9d1FlcpVHyfCt49PJl3Zqf2/Pm2m3yxkbGz1+tVI01P7HqQ861yXkx8h44Fah8saquXbzPK4XJ5GaqoY1sdWIc48yTcc9DtFBlGb7Lp08ylqcWpFtIbzrUbZ13fKeTtNXoRqn2yYNJabcL0Rs96j1PyidGJkYEXC7Bn73ymtBDEL6bDnzNq7lz064phOo+RaLZ9PMyPL1X+x4FEtp5mU52N0zU0qan/a1qfNtAPJkz8h9U96WM240OEiZvJ3L85JzndVucp/bNoC5DeTIQM8HlKVhub5novtdPIydOh1MHVQk1qCZ2Iyh9Ksxx6qbay23FqGwMnyzyMVDppgZNaBmfHnvuOTxxVuAW5tNMPmuQgXYeeflprYurJqT0/DyCOLU/t8x+0223YnHlnOeax9Yi1X/hFrjNzb9P+eZ6bxXRQyRHUrgAt5hjTI56c1jawYF8I3Q3NsHU/N13ilJaBQm/aR0W8eiLk8Wq/bLbF1bAYbP7s+lJFDqpnvf9Lt8krt/ddPlq5cPEb+0JLbsNgYPPFIhtxNfZZ+SN/wB7j5aLGSqS5fhW3ZdyiIdXFnbAXluH3KCfK7VEItT/AOEiIF5Bt+z5I8r/AGqtn7GLK1BZzGHXafm5NRn7OfEpyX3i26fN/eoaNYzfve70f2UCwamLG4zew53vj910G40s8Gpmaw/02LHmHP7of3GqVWtRYXIBfbvfd97+8aLhrbztP5f752/e6eW1OxHPK707/ZXYakGo/bJx9ujxsXH7oVmaPBqX/CNx7L2IPuf/AJZDH+sNbELWpvrjBfdsXPDdKytGNmvhqMSNIE3Pz8//AD0al1NIylybdY/ZXZmi8Gp/bIAL6PZsbcDEOT7VALfUjFf7r+Pb82AIh/d71aka1+2253PnY2B8/Soh9j8i/wBhkyd277/92nYzjJ22/wDJV3KWo22o/Z9N330Zb7RFnEQ/Sri2+of2vJ/pybfIX/lkM/eaq2p/Y/sul5Mm0Txbfv8ANX1Nv/az/f3eQuPvdNzUFynLk27/AGV3RBFFfLYXpnvFcjzOkYx04qWe21Hdb41BfvfNmFeeO1Ru1r/Zd+QXKfvM/e9Ksym0LW+S+d3yff8ASnYzcne9u/2V2MvT7bUf7c1T/iYJjEWMQj0PWrJtNVNmo/tJPN3jnyFx1ptj9l/tzVMF9xEWR83oasgWAtFwZPL3gZy/XNJI0qVJcy06R+yuwNaah9qjI1L5QpyPIXPaqrWeom2v86mOS+P3C+ner7/ZRdJnzN+04+/7VWk+yC2vQ3mfebP3/SixnCctNO32V3Ktlaah/ZemY1LHyx5HkL029K0Daah53/IUITb93yFzmqdk1mNK0zPmYxHj7/XbWgv2Q3JI3+Zt5+/0oS0HVnLmenf7K7laW11I2zH+1AG9fIXHWq9zZ6h/a9jjVD9yXJ8heny1cc2P2WT/AFnl5Ofv+tVrl7MazYD95kpLj7/+zQ0OnKV9u/2V2JYrTUfPnB1Q4yMfuE9KatpqIsov+Jqc4XP7hPapYfsYubr/AFmSRu+/6Ui/YhYQ58zZ8uPv+1FieeV9u32V2FNnqPn5GqkJt+75CZzVKwtNR+z3ZGqnPnvj9wnrWp/opuOkm/b/ALfSqditn9nu22vt85933+eadgjUlyvTt9lD5bPUPMg/4mh4bn9wn9009LS/82TOpHHGP3KelSubZJLf7+d3y/e/umlT7OLib7+7A3fe6YosRzytt0/lXcy9Ts9R/sw/8TQ5Ei5/cpz84q+9pf8AnREamwABBHkpzVPURbJoxwshXzFwPn/56Vpv9nNxDkOXwdv3umKLFynLlWnV/ZXkQra3wWTOpEnnH7leKa9rfbYR/aZzuGT5K88GpwLULPtDgc7+G9KaVtfKtsK+zcNn3uOKLGanLt/5KirpDo0WoZtmAFw/y7fvVbmZA9r/AKMxyf7n3eDVXSFuDFqA8yPzDcPtO3gdPer0izb7cCSPIPzZXrwenNMdVr2j/wCD2IoWT7bdD7O3G35tnXjpWLqrxjwuxFo/+uX5dn/TYVtwrcfbro74tny4G05zj61j6mLoeF2/exbxKnOz/psPepexrQt7SPrHuX7mRf7SscWj9H52Dj5elLbSDztQP2NuHGPlHzfIKdcrc/2hY/vYsfPn5OT8v1otI7vztQ3zoSXGz5OnyCgi65fl5/zFRXxplhmyYnzE4wPl+agO58Wp/oxA+yfe44+Y1LHDc/2bZA3SqwdcnYOeajMVz/wliEzgp9kx9wf3qGapr3ttpdyUM39l3pFoRzJ8vHNWLh3FzYf6MSSW7j5flqARzjTL4m6DElyp2j5frU88cv2iy/0jnLZO0c/LRcxdr9OvfsCPJ9uvP9Hx+7TByPm+9WfpEkv/AAjFqfs2Tx8uR/e61oJHIb67H2k58tMfKvH3vas/S45v+Eatv9Kw3rtXH3qXUtW5em8e/ZmqWcamAISV8r7+Rxz0qsGYWWp/uejycZHPy1Y8uT+0gfPbaIvu4HPNVQr/AGLVMzn78mOBx8tBlG35d+5FqzN5mifuc5uF5yPl+U1oxyOb+YeRgBV+fI+brWbqqyZ0bE5x9pTPA5+U1fiST+0Zz5527FwuBkdaEVNL2a9H37lISSDRIWa1JbcvyZH96rsjv/aduPJyPKkOcjjlKqiOZdHhU3I37l+faMfeqxKj/wBq2379seTJxgc8p7Uwla72+137FHSmk3awBbnJnb+IfNxVqGWYWmn4tichQfmHy/LVbS4pc6uPtPzGdsHA+XjvU0UU5s9PK3ZHCbvlXn5fpSRdSzk9unfsWY5Zvt8y/Zjt2L824c9aytZeU+FbnNv26bh/fFakUcv9oTD7UxGxPl2r789KytYjdfCtzuumYY64UD749qJbBQt7SO28e5r3Ekv2y2xASMNk7hxxRA8purvMGACuPmHzfLROkn222xOwHzcYHPH0oiRzc3YE7Dlew+X5aZhpy9NvPuIHmFrFi1JO4fLvHHNVTJMPEfFtlfs33tw/vVZMcptYcXjA7hl9q88/Sq4SX/hISv2nj7PnG1c/e+lNmkLe9ts+5Kjz/YZ/9G53yYG8c/MaWaWYS2ObbkyH+McfI1J5cv2G4xdnO58Havy/Mfaknil87T/9KY/vDn5V5/dt7UugtLvbr37EqSTfbpx9n+XYuDuHPWsnSXnbwygS23He/G4f89WrSSOX+0LgfbGHyL8u1eOvtWTo0cv/AAjEZW+KfO/O1cf61vajqawS5Om8e/Zm28k/2uD/AEbja2TuHFRtJL9nvswYxuI+Yc/LRIHF9br9sblG+XC/N79KiKMIb8/bSc7uML8vy/SnoYpLTb8e5Bqks/2bTD9n5+0RZG8VeV5P7Uk/cnHkrzuH95qztUVza6Xi+PNxF82F5/Sr8auuqyBrkn9wvBCg/ebnpSNJpezW3Xv3RG0kx06+zb8/vONw54q1JJPmDFvxu+b5xxxVMhzpl/8A6USR5nzYXjj6VbnV824+0kHd6L83H0pmckr9OvfsUbB5hrmqZtyBiLB3D0NXlkuBAP8ARcMG+7vHrVOwjca5qf8ApRY7YvlwvHDe1W9r/Z/mvTncPnwvr06UDq25lttHv2Q95ZxcIBb5TacneOOlVzJP9mvM256tj5xyMVOyOLmPN0QNp+XC89Paop4pBbXZ+1MMhiOF+Xj6UERtpt+Pcr2kkx0zTP8AR+cR5+ccfLV8yz/aNv2f5Nv3t4rOtFcaTpebsjiPJwvPy9OlX8H7Vxd87PuYXPXr0oVrF1UuZ7de/cb5s5tnJtsNuPG8etVrqSb+2bDFvkbJed44+7UmMWsoN+D8x+f5eOagvP8AkM6eTebfkl4+Xn7tJ2HTS5nt179i/G8vnT/uOMjB3Dnio0eU2MP7n5sJxuHHSkjYCe4zeDqOMr8vFMVlOnw4vVXhPnyvPSndGfL5du/YuF5fNwIspjruHWqFhJOba8LQYYTvtG4c81bDp5+ftg6fcyv51Rs3QW15vvF/1z/Nlfl5ouhwj7r07dzQd5fMh/dcbjn5hxwaVGfz5QY/lGMHPXio5ZYxJBm5QDcerD5vlNJHPF9on/0lM8cbhxxRdEcrtt08+5V1J5jpLHyxv8xcjd28wVoMZDLFhBs53EnkVk6hJENGKm9TiRfm3Lz+8rReeDzoibtBwfl3r81K5pKL5dur7+RPmTbJ8gyM7eetRlptsH7td5YbxngDHao/Pg2zD7ZGc5/jX5eKYJ7cQ26i9jOCPmMi/NxRoZqD7fmY2k2Onm11M5lMYnfcdzcVeuLGw/0EMZQCfkw7c/LTtJeXytQPkDcLh8Lu+90q3K82+0xbqcnn5/u/KaDpq1Z+0er+/wAjOh0/T/t90v7/AHgLkbn6YrG1Ww03/hGHbdNt81Ru3N/z1Ga6mGSf7bdD7ONo24bf1OOlZN+058Mtm3UN5q/Lv6/vhUtaG1CtNVI+8949Rk+maWmp2GBNnD4G5+Rtp9pZ6YZdQAE5AbDDL8DaK0LmWf8AtOxH2Ychznf0OOnSkt5LoXGoH7Kv3xj951+RfanoQ6s3HWT2/mX8xkJp+lrptiTHNgyLgkvzzSSafph8UxoYpc/ZSdv7z+91rRjkuv7Nsv8ARUJ8xcjzOnP0ppkuf+ErXNsuPsnXzP8Aa+lJo0VWpeXvPaX2igNO0n+y74iGUgM+f9ZVmXT9J8+xxby7STjiT+7VsS3X9nXmbVM5kwPM6/pU88t19ps8WyZy2f3nTj6U7Ih1ql/ifX7XkZiabpIvrv8A0eXiNc8Sf7VUdNsdJbw1bsbeRhkc4k67q6JJLn7Zcn7MmdiY/edfve1Z+lS3Q8N2+y2QsRjHmY/i+lFlcqNapy/E94/a8mOax0r+0ADbvu8vj5ZPWqo0/S/sOpn7O+A8mch/7tbRkuftwxbLjy+T5nTn6VV825+xalm2QHdJj95/s/SixnCrU/mfT7XmZeo2Gm50bZA4zcLjh/7prQisdLGoz7YH8zYu7h/ek1KS5xpH+jrzcJu/edPlNXopLk38wa3QKEXB8zr19qaWo51J8i957P7XmYn2DSRo6bYJCm8ZJEmfvValstLXVbYeQ+4xSY+V/VKnE12dJjJtkLbhx5nH3vpVmWSf+1Lb9wuPKkyd/TlPaiwSqzu7yf2vteRhaTYaS8mrBreRlFw2eJOmOlWorDSRY2O+1fBC4+WTjip9GlufO1Um2QYuGx+868D2qzHJcG0sStsh4TOZMY+X6UJKxVWrU537z6fa8ipDp2ktfTBbV94RckrJ05rL1fTtKHhe6aO2cDHPD/3hXTpJcfapc26hdq4PmfX2rM1l5v8AhGLkvCobHTfn+IUmlYVGtU9pH3nvH7QsumaULy3T7M24hscP6UR6XpQnus2zdRnh/StKZpftlv8AuhjDfxe1JFLP59yPJXgjHz9ePpVWRj7apb4nt/N5maNO0c2kRNq+wkYGJOuarHTdKHiLYbZt32fPR/WtoSTm1iYW6bty5Xf05qvvnHiDAhXabfk7+fvUNFwrVPe957P7RTOnaT9jnP2VsBnz8sn940XGn6X5un4tnwZDj5ZOmxq1S8xs5SIl3ZfALcdTTZnn8yy/crnec/P0+RqVkSq07v3n1+15GamnaT9uuAbV9wRSflfpzWZotlpbeF42ktWILPxtf/nocV00TTfb5/3S7di4O/61maI8/wDwja7YVJ3Scb/+mjUrK5tGtPk+J7x+15Me9hpY1C2AtW3bG2na/Apq6fpnkX+y16bs/K3Py1pymf7dbnyk2bWz83INNLTGG9zEgxu24br8veqsYKrOy95/f5mLqdjpq2umEWhAM8QA2tkCtBdPsW1R82/PkryQ395qTVTP9m03Eab/ALRFuG7gVfUv/acg2jHkrznvuapsVOrPkXvPr180ZLWOnDTL8i2IUeZkYb0q1cWGn7rTdbE5b5DhuOKlcynTr75F3/vMDPtVmcy7rfCL9/5uenFUTKrO/wAT69fIxrCxsDrupqIDuCxZOG9Gq0+n6WLXm1Plbh8uG65p9g0h13VAyKFCxYOeTw1Wy1z9mBEUfm7vu7uMZo0HVqz517z2j18kVnsNPa4jVrYlsHBw2B0qA2Vh9nvcW5GCwbhueK1SZPPTCLs2nJzzmoJPNFvd5Rf4tuD1GO9BlGrP+Z/f5mXaWNgdK00/ZsqRHxhuu2ro0+wF3gWuH2Z3YPTNFp5h0vTPlXdiPcM9Plq7mT7Vgqvl7eDnnOaSLqVZ3fvPr18zNNhpptJCbL5NxypQ8nNV76wsF1nTQ1qDlJcYUnH3a2AZzbvlY/NycDPHWoLnf/a9jhV27JNxJ5H3elDCnWnzP3n16+RBFYWHn3P+iDIIydp54pqWGnnToD9kXYdmF2njpWjH5nn3GQuzjb69O9NjEosodoXfhcjt2zTI9rP+Z9OvkQnT7L7SP9ETft+/t4+lUbG1sza3260BQTyAgr157VtfP5v8Pl4/HNUdO84QXZYR7/Pk24zjr3pDhUlyvXt1Feys99tm1XJb5cr935T1ojs7M3U+LVN3y5YqMHirb790P3fvfN+R6UIH86XO3bxj16UGftJW36d/Mw9StbNNFObJSvmqAoQcfvK0ntLUzw5skLAHDbB8o9Kh1ITnSm2+UG8xcgg4/wBYKvN9o86PBj8vndwc5oNpVJcu/V9X5FZba0xORYgdd37sfN9KY1rZtFb/AOgLtLDC+WPl471cH2n95kw9fkwD+vNNIuCsWWiD5+bg46duaDNTff8AFmfpUcixaj/pEhPnvg4HHH0q28cjfY8XEgIPPA+b5fpRRVJFVJPnb/rYIYZPtdyftEm07cDA44+lZGrwTJ4acC6k3CROcD/nqPaiioezLoTftY+sTQuLeX+0bH/S5cYcEYXnj6U63t5vOvh9rl5cYOF4+Qe1FFCM+d8vy7L+YrJbzDTrMfbJs+YuThefm+lRNBL/AMJYg+1S4+yZ6L/e+lFFN9DaM3eXpLoiwbeVdMvAbuYnMhzhf8KsTW0v2i0/0qbIJycLzx9KKKDJ1Hf7+i7Cpby/bbk/apeY0xwvH3vas3SLeVvDNti6lBxnOB/e+lFFLqXGb5H6x6eTNMwy/bxi5lx5fIwvPP0qqYZPsGpA3MnLSc4Xj5fpRRTZEJvT5fmQ6nBJnRv9Jl4uEzwOflPtV9LeT+0Jm+1S4KLxheOvtRRQipzfIvR/mU4reVtFiBupclgd2Bn730q1NDJ/a9qftEuBDLxgc8p7UUUClN8z/wC3vyK2kQP5uqj7RLlp2weOOB7VatreR7Gy/wBJlBVVJIA54+lFFCFWm+Z/L8idY3+1ynz5MbVwMDjr7Vla3C//AAjV0pnkJI68cfMPaiiiWw6En7SPrE05o3+2W3758fN6c8fSkihb7RdnzpPmK46cfL9KKKZlzPl+X6iLA4s4l8+XIK/Nxk8/SoDC/wDwkIfz5MfZ8beMdfpRRQVGbvL5k4hb7JOvnyfMznPHHJ6cUlxG4m0/98/Ehz05/dt7UUUhKTu/n+QsUTf2lct50mCijHGB+lZejwsfCyoJpAQ8nzDGf9a1FFLqbRk+T5x/JmtJE3262bzX+VW44waYIysWoHzHO4see3y9qKKoxUnp/XUr6kha100F2yJ4ue5q4q/8TSRsn/UqMdvvNRRSLk/c+/8ANEMiEadfje2T5hz6cVZnXL253MMP+fFFFMzb1+/8inYpt13U23MdyxcHoOGq75JNv5fmSA5+8Dz1oopDrSfMvSP5IlZcyK2TwDx+VV5UxbXeGb5gx+nHaiigzi9StZxn+ytNXe3AjOe5+WruzF3v3NymMdutFFC2LqN8z+ZG8GbWSPzJPmJO7PI5qvdRk6vpx3thEl4z977vWiihjpyfN8n+RZjj/f3JLP8AMR36cdqasI+wwpvf5QnIbk9KKKaJ5nf7icxjzQ25umMZ4rP0+BRbXi7nw0787uRz2oopLccJPlfyLskQLwnc/wAp/vHng9aSKIC5mO5+dvG4+lFFBHM7f13M/VLZW0hl3yDEinIc5/1grQeBTNE26T5QRjccHiiin1NZSfKter/QcYFw/wA0nzf7Z4qJrVDHAu+XCHP3zk8d6KKDJTl3P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15926=[""].join("\n");
var outline_f15_35_15926=null;
var title_f15_35_15927="Seborrheic dermatitis face 3";
var content_f15_35_15927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65167%7EDERM%2F59104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65167%7EDERM%2F59104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis of the face and beard area",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15927=[""].join("\n");
var outline_f15_35_15927=null;
var title_f15_35_15928="Diagnosis and treatment of Penicillium marneffei infection";
var content_f15_35_15928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of Penicillium marneffei infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Khuanchai Supparatpinyo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Thira Sirisanthana, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15928/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/35/15928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillium marneffei is an important cause of morbidity and mortality in HIV-infected patients in Southeast Asia and occasionally in immunosuppressed patients who have had travel-related exposure to this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This systemic fungal infection was commonly diagnosed prior to the era of potent antiretroviral therapy (ART). The widespread use of ART has led to a significant decline of opportunistic infections (OIs), including P. marneffei infection in the highly endemic areas. However, despite the wide availability of ART in Thailand, P. marneffei infection continues to cause considerable morbidity and mortality in AIDS patients who are either unaware of their HIV infection, who do not have access to ART, or who have suboptimal responses to HIV therapy.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of P. marneffei will be reviewed here. The mycology, epidemiology, and clinical manifestations of P. marneffei are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis is usually made by culture of the fungus from blood, skin biopsy, bone marrow, or lymph nodes, or by histopathological demonstration of the characteristic morphologic findings of this fungus in biopsy material [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Due to the importance of rapid initiation of treatment and the delay associated with cultures, a presumptive diagnosis can be quickly made through microscopic examination of Wright-stained samples of skin scrapings, bone marrow aspirate, or lymph node biopsy specimens. The organism can also be identified on blood smears of patients with heavy fungemia (",
"    <a class=\"graphic graphic_picture graphicRef58588 \" href=\"UTD.htm?7/58/8099\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence of oval or elongated yeast-like organisms with clear central septum is a unique feature of P. marneffei. The presence of a centrally located transverse septum (eg, \"cross wall\") differentiates P. marneffei from Histoplasma capsulatum (",
"    <a class=\"graphic graphic_picture graphicRef71699 \" href=\"UTD.htm?5/0/5124\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. marneffei can be readily isolated from various clinical specimens. The organism typically takes about four to seven days to grow, although occasionally growth can take a few weeks to occur. Bone marrow culture and lymph node biopsies are the most sensitive, followed by cultures of skin lesions and blood, including conventional blood culture systems (",
"    <a class=\"graphic graphic_table graphicRef62907 \" href=\"UTD.htm?28/35/29243\">",
"     table 1",
"    </a>",
"    ). P. marneffei has also been isolated from cultures of stool, urine, cerebrospinal fluid (CSF), and joint fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal cultures at 25&ordm;C on Sabouraud dextrose agar demonstrate characteristic features that include a flat green surface and underlying deep red coloring (",
"    <a class=\"graphic graphic_picture graphicRef76600 \" href=\"UTD.htm?18/61/19411\">",
"     picture 3",
"    </a>",
"    ). Microscopically, the fungus has typical filamentous reproductive structures of the genus Penicillium (",
"    <a class=\"graphic graphic_picture graphicRef78922 \" href=\"UTD.htm?23/62/24544\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mold-to-yeast conversion can be achieved by subculturing the fungus onto brain-heart-infusion agar and incubating at 37&ordm;C. Demonstration of this conversion is required before concluding that the isolate is P. marneffei. Alternatively, an exoantigen test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/8\">",
"     8",
"    </a>",
"    ] and a polymerase chain reaction (PCR)-hybridization assay [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/9\">",
"     9",
"    </a>",
"    ] have been described, which can be used to rapidly identify cultures of the organism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\", section on 'Mycology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. marneffei can be presumptively diagnosed, in a compatible epidemiologic setting, several days before the cultures are positive through microscopic examination of Wright-stained samples of blood, bone marrow, touch smears of skin or lymph node biopsies, or Giemsa stain of bronchoalveolar fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/1,6,10,11\">",
"     1,6,10,11",
"    </a>",
"    ]. Wright-stained samples show many intracellular and extracellular basophilic, spherical, oval, and elliptical yeast-like organisms. Some of these cells have a clear central septum, which is a characteristic feature of P. marneffei (",
"    <a class=\"graphic graphic_picture graphicRef58588 \" href=\"UTD.htm?7/58/8099\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79630 \" href=\"UTD.htm?39/43/40627\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since the cell wall and the cytoplasm of P. marneffei cells cannot be seen well with hematoxylin-eosin staining of tissue sections, Grocott",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver or periodic-acid Schiff staining is preferred. The organisms appear as unicellular round to oval cells within macrophages or histiocytes. Extracellular elongated or sausage-shaped cells with one or two septa may also be seen.",
"   </p>",
"   <p>",
"    In one study of liver biopsies from 30 HIV-infected patients with disseminated P. marneffei infection, histopathological findings were classified into one of three patterns: diffuse, granulomatous, and mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/12\">",
"     12",
"    </a>",
"    ]. The first pattern showed a diffuse infiltration of foamy macrophages that contained numerous P. marneffei. The granulomatous pattern showed multiple granulomata with various degrees of inflammatory cell infiltration. The mixed pattern showed features intermediate between the first two categories.",
"   </p>",
"   <p>",
"    Use of fine needle aspiration of lymph nodes has also been reported in patients with HIV and lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/13\">",
"     13",
"    </a>",
"    ]. In all cases, intracellular and extracellular yeast forms were visualized with the characteristic cross-septation of P. marneffei. All diagnoses were confirmed by culture. This technique is particularly helpful in cases where there are no skin lesions and enlarged lymph nodes are confined to the deep intra-abdominal region [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical techniques have been described for the identification of the tissue form of P. marneffei. In addition, P. marneffei has been identified from a skin biopsy specimen through PCR, using a set of primers specific for the fungus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic assays are not widely used because of limited data regarding diagnostic accuracy and restricted availability of the required commercial reagents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research is ongoing to further assess various methods, such as the immunodiffusion test, the indirect fluorescent antibody test, the enzyme-linked immunosorbent assay (ELISA) or the Western immunoblot test for serologic testing in asymptomatic individuals as well as symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/13,16,17\">",
"     13,16,17",
"    </a>",
"    ]. Whether serologic testing may enable the identification of asymptomatic individuals who may benefit from preemptive treatment is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Molecular diagnostics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither antigen testing (immunodiffusion, latex agglutination, or ELISA) nor PCR-based techniques using serum is currently in clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several researchers have evaluated various diagnostic methods, such as latex agglutination or polymerase chain reaction (PCR), to detect P. marneffei antigens in serum or urine from infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/15,16,19,20\">",
"     15,16,19,20",
"    </a>",
"    ]. These diagnostic modalities need further evaluation in clinical trials to assess their utility in diagnosing active penicilliosis or in predicting relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/9,20-24\">",
"     9,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Galactomannan testing, which is primarily used for detection of aspergillosis, can show cross-reactivity with P. marneffei [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/25\">",
"     25",
"    </a>",
"    ]. For example, positive serum galactomannan tests were reported in one small case series of three patients who had pulmonary infiltrates secondary to culture-proven P. marneffei infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the titers in patients with penicilliosis appear to be lower than those noted in patients with aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/27\">",
"     27",
"    </a>",
"    ]. Galactomannan testing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leading alternative diagnoses to consider include tuberculosis, melioidosis, and histoplasmosis. Common clinical findings in these infections include fever, weight loss, cough, anemia, lymphadenopathy, hepatomegaly, and splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/28\">",
"     28",
"    </a>",
"    ]. However, skin lesions are more commonly present in P. marneffei than in other common opportunistic infections; bedside microscopic examination of scrapings from skin lesions can easily lead to the correct diagnosis due to its unique morphology (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 30 clinical isolates from northern Thailand revealed that all were highly susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , miconazole, and 5-flucytosine.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    had intermediate antifungal activity, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    was the least active [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has also demonstrated good activity against P. marneffei in vitro, comparable to itraconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/30\">",
"     30",
"    </a>",
"    ]. However, P. marneffei is resistant to fluconazole.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    , an echinocandin, also has in vitro activity against penicillium species [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/31\">",
"     31",
"    </a>",
"    ]. One in vitro study evaluated whether the antifungal agent, micafungin, may be additive or synergistic with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/32\">",
"     32",
"    </a>",
"    ]. Micafungin led to synergistic activity against 20 P. marneffei isolates when combined with itraconazole or amphotericin B; no improvement in activity was noted for fluconazole. These in vitro suggest that combination antifungal therapy may have a role in the treatment of patients with P. marneffei infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic interventions need to be timely to be optimally effective. Delayed diagnosis can be associated with high mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]. This is particularly true in patients with severe disease (eg, respiratory failure or circulatory collapse) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/33\">",
"     33",
"    </a>",
"    ] or moderate disease (characterized by multiple organ involvement without respiratory or cardiovascular failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to initial treatment depends on disease severity and the patient's ability to tolerate oral therapy. For patients with severe disseminated disease or who cannot tolerate oral medication, intravenous therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for two weeks) followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice daily for 10 weeks) is the preferred regimen for P. marneffei [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/2,34\">",
"     2,34",
"    </a>",
"    ]. This recommendation is based on an open-label noncomparative study of amphotericin B followed by oral itraconazole for 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/35\">",
"     35",
"    </a>",
"    ]. Of the 74 patients treated, 72 (97.3 percent) responded without serious adverse effects. Amphotericin B should also be used in patients with clinical signs or symptoms of central nervous system involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, two small reports suggest that patients with mild disease can be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice daily for 8 to 12 weeks) without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/2,33,37\">",
"     2,33,37",
"    </a>",
"    ]. For example, in a report of 46 patients from Northeastern India, treatment with oral itraconazole alone was effective in all but one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/38\">",
"     38",
"    </a>",
"    ]. The oral formulation of itraconazole solution is preferred to the capsule due to better absorption.",
"   </p>",
"   <p>",
"    When patients are switched from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice daily), it is important to check for potential drug interactions with ART that can increase or decrease itraconazole levels, depending on the interaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some preliminary data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    may also be effective in the treatment of penicilliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After initial induction therapy, long-term suppressive therapy is usually required to prevent relapse. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Maintenance therapy (secondary prophylaxis)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We also recommend the initiation of ART in any patient who is not on HIV therapy, since most patients who present with P. marneffei have advanced immunosuppression at the time of diagnosis. We usually initiate ART within approximately two to four weeks of antifungal therapy due to the benefit seen with earlier initiation of ART in other infections (eg, tuberculosis).",
"   </p>",
"   <p>",
"    The immune restoration inflammatory syndrome (IRIS) has been reported uncommonly in patients with P. marneffei infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It usually occurs within a few weeks or months after starting ART, suggesting a possibility of immune reconstitution unmasking active disease. ART should be continued even if the IRIS occurs. In patients with severely symptomatic IRIS, short-course glucocorticosteroids may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    should be monitored for infusion-related adverse reactions, nephrotoxicity, and electrolyte disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If possible, serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    levels should be obtained to ensure adequate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/2\">",
"     2",
"    </a>",
"    ]. Drug levels should also be considered if potential drug interactions exist. Detailed information on timing of drug monitoring is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates are high from disseminated P. marneffei unless the infection is diagnosed early and appropriate therapy is instituted promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/1,5,43-45\">",
"     1,5,43-45",
"    </a>",
"    ]. Response rates of 59 to 77 percent, initially reported in 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/1\">",
"     1",
"    </a>",
"    ], have improved to as high as 97 percent in later reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY (SECONDARY PROPHYLAXIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses of P. marneffei infection are common. In the pre-HAART era, one study found that the relapse rate of this infection was 50 percent after discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/37,46\">",
"     37,46",
"    </a>",
"    ]. A placebo-controlled, double-blind, randomized trial was conducted from 1993 to 1996 to evaluate the efficacy and safety of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg daily) after the successful completion of standard antifungal therapy for disseminated, culture-proven P. marneffei infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/46\">",
"     46",
"    </a>",
"    ]. Of the 71 patients enrolled, 36 were randomly assigned to receive itraconazole; none of the patients were taking antiretroviral therapy. Two patients were lost to follow-up. The study was terminated at the interim analysis, since all 20 relapses of P. marneffei infection occurred in the placebo group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Discontinuation of secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era of potent ART, the clinical outcomes after discontinuation of maintenance therapy appear to be much more encouraging, although there are no randomized controlled studies to address this issue. Only small case series and retrospective studies have been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective cohort study was conducted to determine the relapse rate of P. marneffei after the discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      secondary prophylaxis in 33 HIV-infected patients who had attained CD4 cell counts of 100",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      or greater for at least six months on ART [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/47\">",
"       47",
"      </a>",
"      ]. No relapses were observed after a median follow-up of 18 months (range 6-45).",
"     </li>",
"     <li>",
"      Among another 26 patients with penicilliosis, 18 patients discontinued maintenance therapy after the CD4 count had risen to a median of 95",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/48\">",
"       48",
"      </a>",
"      ]. Despite this low level of immune reconstitution, only one patient relapsed after a median follow-up of 35 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest lifelong maintenance therapy until the CD4 cell count is &gt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    for a minimum of six months on potent ART. Secondary prophylaxis should be reintroduced if the CD4+ count decreases to &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    If a patient has a recurrence of P. marneffei infection, a complete course of induction therapy will be needed again followed by prophylaxis at 200 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PRIMARY PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention of P. marneffei infection with an antifungal agent is not generally recommended, but may be a reasonable preventive measure in areas of high endemicity. For example, in northern Thailand, disseminated fungal infection due to P. marneffei, Cryptococcus neoformans, and Histoplasma capsulatum, as well as other fungal infections (eg, candidiasis), are common, accounting for over a third of all reported AIDS-defining illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Northern Thailand, the national guidelines recommend use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg orally once daily) for primary prophylaxis of systemic fungal infections in all HIV-infected patients with a CD4+ cell count of &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/50\">",
"     50",
"    </a>",
"    ]. This recommendation is based on the results of a prospective, double-blind, placebo-controlled trial in 129 Thai patients with a mean CD4 cell count of 77",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15928/abstract/50\">",
"     50",
"    </a>",
"    ]. In the intent-to-treat analysis, the proportion of patients who developed a systemic fungal infection was significantly lower in the prophylaxis arm than the placebo arm (1.6 versus 16.7 percent). One patient in the itraconazole arm developed P. marneffei while seven patients in the placebo arm developed cryptococcal meningitis and four patients were diagnosed with P. marneffei infection. No survival advantage was observed in the itraconazole arm; of note, the vast majority of patients were not taking ART during the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Discontinuation of primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been no formal study on the safety of discontinuation of primary prophylaxis for P. marneffei infection. However, based on the secondary prophylaxis data noted above, it is likely safe to discontinue primary prophylaxis for P. marneffei in AIDS patients who have attained a CD4+ cell count &gt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    for at least six months on ART. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Maintenance therapy (secondary prophylaxis)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive diagnosis is made by culture of the fungus, most commonly from blood, skin biopsy, bone marrow, or lymph nodes. A presumptive diagnosis can be made from histopathology in the appropriate clinical and epidemiologic setting. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antifungal therapy for all patients with penicilliosis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For the patient with severe disseminated disease, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day for two weeks) followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg PO twice daily for 10 weeks) rather than an alternative antifungal regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For the patient with mild to moderate infection, we suggest itraconazole 200 mg orally twice daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the initiation of combination ART for AIDS patients with P. marneffei infection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We prefer to initiate therapy within two to four weeks after starting antifungal therapy. It is necessary to check for potential drug interactions between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      and certain antiretroviral medications, which can either increase or decrease itraconazole levels. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After induction therapy, we recommend maintenance antifungal therapy for secondary prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg daily) is effective, although clinicians need to check for drug interactions between this antifungal agent and any of the patient's antiretroviral medications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest discontinuation of maintenance therapy once CD4 counts are &gt;100",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      for at least six months on ART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maintenance therapy (secondary prophylaxis)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest primary prophylaxis for AIDS patients with a CD4 count &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      in areas of high endemicity (eg, Southeast Asia) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/1\">",
"      Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/2\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/3\">",
"      Supparatpinyo K, Sirisanthana T. Disseminated Penicillium marneffei infection diagnosed on examination of a peripheral blood smear of a patient with human immunodeficiency virus infection. Clin Infect Dis 1994; 18:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/4\">",
"      Hung YT, Yang SP. Pancytopenia in a Southeast Asian Woman with HIV Infection. Clin Infect Dis 2009; 49:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/5\">",
"      Jayanetra P, Nitiyanant P, Ajello L, et al. Penicilliosis marneffei in Thailand: report of five human cases. Am J Trop Med Hyg 1984; 33:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/6\">",
"      So SY, Chau PY, Jones BM, et al. A case of invasive penicilliosis in Hong Kong with immunologic evaluation. Am Rev Respir Dis 1985; 131:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/7\">",
"      Louthrenoo W, Thamprasert K, Sirisanthana T. Osteoarticular penicilliosis marneffei. A report of eight cases and review of the literature. Br J Rheumatol 1994; 33:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/8\">",
"      Sekhon AS, Li JS, Garg AK. Penicillosis marneffei: serological and exoantigen studies. Mycopathologia 1982; 77:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/9\">",
"      Vanittanakom N, Vanittanakom P, Hay RJ. Rapid identification of Penicillium marneffei by PCR-based detection of specific sequences on the rRNA gene. J Clin Microbiol 2002; 40:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/10\">",
"      Chariyalertsak S, Sirisanthana T, Supparatpinyo K, et al. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis 1997; 24:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/11\">",
"      Heath TC, Patel A, Fisher D, et al. Disseminated Penicillium marneffei: presenting illness of advanced HIV infection; a clinicopathological review, illustrated by a case report. Pathology 1995; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/12\">",
"      Yousukh A, Jutavijittum P, Pisetpongsa P, et al. Clinicopathologic study of hepatic Penicillium marneffei in Northern Thailand. Arch Pathol Lab Med 2004; 128:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/13\">",
"      Chaiwun B, Khunamornpong S, Sirivanichai C, et al. Lymphadenopathy due to Penicillium marneffei infection: diagnosis by fine needle aspiration cytology. Mod Pathol 2002; 15:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/14\">",
"      Tsunemi Y, Takahashi T, Tamaki T. Penicillium marneffei infection diagnosed by polymerase chain reaction from the skin specimen. J Am Acad Dermatol 2003; 49:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/15\">",
"      Vanittanakom N, Sirisanthana T. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Curr Top Med Mycol 1997; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/16\">",
"      Cao L, Chan KM, Chen D, et al. Detection of cell wall mannoprotein Mp1p in culture supernatants of Penicillium marneffei and in sera of penicilliosis patients. J Clin Microbiol 1999; 37:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/17\">",
"      Vanittanakom N, Mekaprateep M, Sittisombut N, et al. Western immunoblot analysis of protein antigens of Penicillium marneffei. J Med Vet Mycol 1997; 35:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/18\">",
"      Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/19\">",
"      Chaiyaroj SC, Chawengkirttikul R, Sirisinha S, et al. Antigen detection assay for identification of Penicillium marneffei infection. J Clin Microbiol 2003; 41:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/20\">",
"      Vanittanakom N, Merz WG, Sittisombut N, et al. Specific identification of Penicillium marneffei by a polymerase chain reaction/hybridization technique. Med Mycol 1998; 36:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/21\">",
"      Kaufman L, Standard PG, Jalbert M, et al. Diagnostic antigenemia tests for penicilliosis marneffei. J Clin Microbiol 1996; 34:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/22\">",
"      LoBuglio KF, Taylor JW. Phylogeny and PCR identification of the human pathogenic fungus Penicillium marneffei. J Clin Microbiol 1995; 33:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/23\">",
"      Prariyachatigul C, Chaiprasert A, Geenkajorn K, et al. Development and evaluation of a one-tube seminested PCR assay for the detection and identification of Penicillium marneffei. Mycoses 2003; 46:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/24\">",
"      Desakorn V, Simpson AJ, Wuthiekanun V, et al. Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicilliosis marneffei. J Clin Microbiol 2002; 40:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/25\">",
"      Huang YT, Hung CC, Liao CH, et al. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol 2007; 45:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/26\">",
"      Huang YT, Hung CC, Hsueh PR. Aspergillus galactomannan antigenemia in penicilliosis marneffei. AIDS 2007; 21:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/27\">",
"      Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006; 19:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/28\">",
"      Mootsikapun P, Srikulbutr S. Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. Int J Infect Dis 2006; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/29\">",
"      Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/30\">",
"      Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997; 41:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/31\">",
"      Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 2009; 53:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/32\">",
"      Cao C, Liu W, Li R, et al. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei. J Antimicrob Chemother 2009; 63:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/33\">",
"      Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002; 45:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/34\">",
"      Al-Abdely HM. Management of rare fungal infections. Curr Opin Infect Dis 2004; 17:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/35\">",
"      Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/36\">",
"      Le T, Huu Chi N, Kim Cuc NT, et al. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis 2010; 51:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/37\">",
"      Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 1992; 75:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/38\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/39\">",
"      Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/40\">",
"      Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg 2007; 77:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/41\">",
"      Manosuthi W, Chaovavanich A, Tansuphaswadikul S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect 2007; 55:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/42\">",
"      Gupta S, Mathur P, Maskey D, et al. Immune restoration syndrome with disseminated Penicillium marneffei and cytomegalovirus co-infections in an AIDS patient. AIDS Res Ther 2007; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/43\">",
"      Deng Z, Ribas JL, Gibson DW, Connor DH. Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis 1988; 10:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/44\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/45\">",
"      Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens. Clin Infect Dis 2007; 45:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/46\">",
"      Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/47\">",
"      Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS 2007; 21:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/48\">",
"      Sun HY, Chen MY, Hsiao CF, et al. Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy. Clin Microbiol Infect 2006; 12:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/49\">",
"      Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994--1998: regional variation and temporal trends. Clin Infect Dis 2001; 32:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15928/abstract/50\">",
"      Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3035 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15928=[""].join("\n");
var outline_f15_35_15928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Molecular diagnostics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MAINTENANCE THERAPY (SECONDARY PROPHYLAXIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Discontinuation of secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PRIMARY PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Discontinuation of primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3035|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/58/8099\" title=\"picture 1\">",
"      Wrights stain yeast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/0/5124\" title=\"picture 2\">",
"      Cross wall PM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/61/19411\" title=\"picture 3\">",
"      Agar colonies P marneffei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/62/24544\" title=\"picture 4\">",
"      Micro P marneffei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/43/40627\" title=\"picture 5\">",
"      Wrights stain P marneffei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/35/29243\" title=\"table 1\">",
"      Isolation P marneffei",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_35_15929="Preoperative evaluation and perioperative management of patients with rheumatic diseases";
var content_f15_35_15929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/35/15929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15929/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/35/15929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15929/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/35/15929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/35/15929/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/35/15929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a spectrum of rheumatic diseases that affect patients of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, clinicians working with patients with musculoskeletal disorders must be aware that there are general and specific issues involved in their pre- and post-operative management [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Areas of special concern for patients with rheumatic diseases who are having surgery will be discussed here. General issues in preoperative medical consultation and perioperative management are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link\">",
"     \"Perioperative medication management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history, physical examination, targeted laboratory studies, and specific imaging procedures are recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients require a careful history and physical examination, with further evaluation indicated in some individuals. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RA is associated with a 60 percent increase in risk of cardiovascular death compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since many patients with rheumatic diseases being considered for surgery are elderly, these subjects may have decreased cardiac, pulmonary, renal, or peripheral vascular function, thereby possibly resulting in a higher risk of an adverse outcome. Determining cardiovascular risk may be more difficult because many patients with rheumatic diseases are not physically active. An exercise or pharmacologic stress test may be necessary in some circumstances to adequately assess the risk of perioperative myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatoid arthritis patients can present a number of complex problems for the anesthesiologist, and effective communication between surgeon, rheumatologist, and anesthesiologist is essential [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/5\">",
"       5",
"      </a>",
"      ]. For example, it is important to inquire specifically about symptoms suggestive of cervical joint involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. The earliest and most common symptom is neck pain with occipital radiation. Recognition of such involvement is important since those with severe subluxation are at risk for severe injury and perhaps death with intubation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of prostatic hypertrophy may need urological evaluation to avoid the need for prolonged postoperative urinary catheterization and the associated risk of urinary tract infection, bacteremia, and seeding of a prosthetic joint. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"       \"Medical treatment of benign prostatic hyperplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"       \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carious teeth, pharyngitis, cystitis, skin infections, and other potential sources of infection must be detected and treated prior to elective surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis, serum electrolyte levels, and serum concentrations of glucose, blood urea nitrogen, and creatinine, as well as a complete blood count and coagulation profile, are usually performed in all patients.",
"   </p>",
"   <p>",
"    Vitamin D deficiency was associated with a suboptimal outcome in a pilot study of patients undergoing joint replacement surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/8\">",
"     8",
"    </a>",
"    ]. However, it is not known if this association reflects a causal relationship and whether such supplementation would have any clinical benefit, although it is relatively simple and inexpensive to correct until additional data become available.",
"   </p>",
"   <p>",
"    An asymptomatic urinary tract infection should be excluded prior to elective orthopedic surgery to reduce the risk of postoperative infection. Some surgeons may, therefore, request a urinary culture. In some cases, joint aspiration, electrodiagnostic studies, and additional imaging studies are needed to clarify the cause of pain and loss of function. There are also some laboratory abnormalities in patients with rheumatic diseases that may require specific interventions prior to surgery (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimizing the patient's medical condition preoperatively may help prevent postoperative problems. General issues that may need to be addressed include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical therapy: Preoperative physiotherapy is beneficial to increase strength and range of motion and to help prepare for postoperative rehabilitation. As an example, greater knee extensor strength in the preoperative period is associated with better physical function at 12 weeks postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weight reduction: Weight reduction may be recommended for obese patients. This will result in less stress on joints. In addition, there is evidence of an increased incidence of infection in obese patients following total joint arthroplasty, as well as increased intraoperative blood loss [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombosis risk: The cumulative incidence of a venous thromboembolism among patients with total hip replacement receiving pharmacological thromboprophylaxis was 1 percent in one study. Patients with rheumatoid arthritis had a reduced relative risk for venous thromboembolism compared with patients with primary osteoarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with SLE also have antiphospholipid antibodies, which are associated with an increased risk of thrombosis. Management of such patients depends upon their specific anticoagulation drug regimen and whether or not they have antiphospholipid syndrome. The specific approaches suggested for the treatment of antiphospholipid syndrome and of other patients receiving anticoagulants are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Perioperative management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'SLE with aPL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medication management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents used for treating rheumatic disease may impact upon surgery. These include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and other disease-modifying antirheumatic drugs (DMARDs), nonsteroidal antiinflammatory drugs (NSAIDs), and biologic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6802267\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged use of glucocorticoids may suppress the normal increase in endogenous cortisol that occurs in response to the stress of surgery. Supplementation of glucocorticoids may, therefore, be needed to mimic the body's own response to stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following two regimens may be utilized in patients considered to have suppression of the hypothalamic-pituitary-adrenal axis who are undergoing major surgical procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach is to provide high doses of glucocorticoid to those with proven or suspected adrenal insufficiency, starting at the time of induction of anesthesia. A continuous infusion of 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      per hour or the equivalent amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      eliminates the possibility of glucocorticoid deficiency as the cause of an adverse event (such as hypotension), thereby allowing the actual cause (hemorrhage or volume depletion) to be identified and treated.",
"      <br/>",
"      <br/>",
"      The glucocorticoid dose can be halved the day after surgery, and the maintenance dosage usually can be resumed the second postoperative day. This amount of glucocorticoid for this amount of time carries a negligible risk of adverse effects; however, prolonged postoperative pharmacologic glucocorticoid therapy can mask symptoms and signs of infection and can produce undesirable side effects.",
"     </li>",
"     <li>",
"      The other regimen utilizes parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      \"boosts.\" Generally, 100 mg of hydrocortisone is given intravenously every eight hours perioperatively, and the dose is slowly reduced (but not the frequency) until the patient can be switched to his or her regular doses of oral medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two regimens are also appropriate for patients with postoperative complications that are life-threatening, such as sepsis with hypotension or hypovolemic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For convenience, we administer intermittent, rather than continuous, parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Prolonged use of glucocorticoids may cause other complications related to surgery, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired wound healing",
"     </li>",
"     <li>",
"      Increased friability of skin and superficial blood vessels",
"     </li>",
"     <li>",
"      Hematoma or skin ulceration due to mild pressure",
"     </li>",
"     <li>",
"      Increased susceptibility of the skin to tears from adhesive tap",
"     </li>",
"     <li>",
"      Increased risk of fracture, infections, gastrointestinal hemorrhage, or ulcer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving 5 mg per day or less of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or equivalent dose of other glucocorticoids) preoperatively need only receive their usual doses of medication, or an equivalent dose if unable to take oral medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    25 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    5 mg intravenously) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. Those undergoing minor surgical or dental procedures, endoscopic studies, or similar minimally stressful interventions may also be managed with low doses of supplemental glucocorticoids.",
"   </p>",
"   <p>",
"    For moderately stressful procedures or postoperative illnesses, such as pneumonia, higher doses of parenteral glucocorticoids are needed (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    50 to 75 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    10 to 15 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/2,15\">",
"     2,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid the antiplatelet effect of NSAIDs during surgery, these drugs should be stopped at least three half-lives prior to surgery. For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , which has a half-life of about 2.5 hours, should be stopped a day prior to surgery, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , with a half-life of 15 hours, should be stopped 4 days before [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , which permanently inhibits platelet cyclooxygenase, is discontinued at least one week prior to surgery to allow production of new platelets.",
"   </p>",
"   <p>",
"    The highly selective cyclooxygenase 2 (COX-2) inhibitors do not interfere with platelet function and, therefore, should not increase the risk of bleeding. However, since COX-2 may have a role in wound healing and renal function, selective COX-2 inhibitors should be used cautiously in the perioperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cardiovascular risks associated with the use of nonselective and COX-2-selective NSAIDs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brief perioperative use of NSAIDs (mean duration of three days postoperatively) was not associated with increased risk for myocardial infarction compared with not using NSAIDs in a cohort of 10,873 patients following total hip and knee replacement (odds ratio 0.95, 95% CI 0.5-1.8), and NSAID use was associated with a reduced hospital length of stay (98 versus 115 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Methotrexate and other nonbiologic DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease modifying antirheumatic drugs (DMARDs) are crucial to the treatment of patients with RA. Although a reasonable concern exists about their potential to increase the risk of infection by affecting the immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/17\">",
"     17",
"    </a>",
"    ], stopping DMARDs prior to surgery may result in flare up of disease activity, which may adversely affect rehabilitation.",
"   </p>",
"   <p>",
"    Continued use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) through the perioperative period was found to be safe in patients with RA undergoing elective orthopaedic surgery in a 2008 review that identified eight published reports addressing this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/18\">",
"     18",
"    </a>",
"    ]. The studies compared continued versus discontinued MTX therapy, or MTX therapy versus therapies other than MTX. Continued MTX therapy was safe perioperatively and also appeared to be associated with a reduced risk of flares. There was little evidence to suggest that stopping MTX preoperatively reduced the incidence of infection or improved wound healing. None of the reports reviewed, however, addressed the issue of safety in relation to comorbidities or age, and most used lower doses of MTX than are typically used in current practice [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/18\">",
"     18",
"    </a>",
"    ]. This approach is also consistent with the recommendations of a broad international panel of rheumatologists regarding the use of MTX in patients with rheumatoid arthritis undergoing orthopaedic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the largest study included in the review, 388 patients with RA undergoing elective orthopedic surgery were randomly assigned to continue weekly MTX (10",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    median dose) before and after surgery or to hold MTX for two weeks before and after their operations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/20\">",
"     20",
"    </a>",
"    ]. Postoperative infections and other complications were significantly less frequent in those who continued MTX than in the others (2 and 15 percent, respectively). Postoperative flares of arthritis were not seen in those who continued MTX but developed in 8 percent of those who stopped the drug. In this study, however, use of other DMARDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , antimalarials) and glucocorticoids was associated with an increased risk of postoperative infection.",
"   </p>",
"   <p>",
"    It seems reasonable to discontinue agents that can cause leukopenia (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ) a few days preoperatively.",
"   </p>",
"   <p>",
"    Although there are currently no data to guide the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    in the perioperative period, others have recommended that it be withheld for two weeks prior to elective surgery and resumed three days following, or whenever the patient is able to take oral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although one study found an increased risk of postoperative infection in association with use of antimalarial drugs, these agents have very long half-lives and persist in tissues. Therefore, it is probably of little use to discontinue them in the perioperative period, and they may be resumed once the patient is able to tolerate oral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Biological agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that interfere with the action of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, or T cell costimulation and agents that deplete B lymphocytes are used in the treatment of RA and other disorders. There is relatively little evidence available regarding the optimal timing for use of these medications in the pre- and perioperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/21\">",
"     21",
"    </a>",
"    ]. Examples of anti-TNF agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    is a recombinant human IL-1 receptor antagonist, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    interferes with the activity of IL-6.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    blocks T cell costimulation. TNF-alpha, IL-1, and IL-6 play important roles in host resistance to infection, and T cell costimulation is important in T cell activation by antigen-presenting cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to perioperative use of the biologic agents is to wait at least one or two treatment cycles without drug administration prior to elective surgery. For example, we suggest scheduling surgery at least one to two weeks after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    treatment and two to four weeks after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    treatment. Similarly, we would wait four to eight weeks after administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    . These agents should not be restarted until external wound healing is complete. Biologic DMARDs should be stopped in the event of a serious infection. They should not be resumed until the infection is eradicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    or other B cell-depleting agents may also be associated with an increased risk of pulmonary infection, but this has not been formally studied in relation to perioperative infection risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/22\">",
"     22",
"    </a>",
"    ]. Based upon an understanding of the mechanism of action and clinical experience, we suggest timing elective surgery for when B cells have returned to the circulation whenever feasible. We do not delay nonelective procedures in patients who have been more recently treated.",
"   </p>",
"   <p>",
"    Reassuringly, serious infection rates in clinical trials were no higher in those rheumatoid patients taking TNF inhibitors than in those receiving placebo, and surgery during and after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    treatment has been performed safely [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/23\">",
"     23",
"    </a>",
"    ]. Many [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/24-27\">",
"     24-27",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], retrospective studies suggest that use of anti-tumor necrosis factor alpha (anti-TNF) therapy does not increase the risk of postoperative infections or impaired wound healing. In one of these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/24\">",
"     24",
"    </a>",
"    ], anti-TNF therapies were discontinued before and after 75 percent of the surgical procedures; in another, anti-TNF agents were stopped in 40 percent of patients prior to surgery, while surgery was performed between usually scheduled doses in the remaining 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    was discontinued about two weeks before and restarted about five weeks after surgery, infliximab about one month before and after, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    two weeks before and six to seven weeks after.",
"   </p>",
"   <p>",
"    The infectious risks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    are similar to those of TNF inhibitors and other biologic agents, but there are no trials which have examined its safety perioperatively. Recommendations by ourselves and others regarding abatacept are, thus, based largely upon these observations and theoretical considerations regarding drug half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/21,30\">",
"     21,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, trials of the interleukin 1 receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    showed that the infection rate was similar to that in patients receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/31\">",
"     31",
"    </a>",
"    ]. These data are somewhat reassuring, although limited, with respect to the safety of using these agents in the perioperative period. Withholding anti-TNF agents perioperatively appears to be the most reasonable and prudent approach in this situation of uncertainty, considering the morbidity of orthopaedic surgical site infections (especially infections of prostheses) compared with a transient surge in disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISEASE SPECIFIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain problems related to particular rheumatic diseases can be anticipated, such as possible atlantoaxial instability in severe, chronic RA. Some of the most common issues arising in patients with Sj&ouml;gren's syndrome, RA, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthropathy, hemophilic arthropathy, systemic lupus erythematous (SLE), and systemic sclerosis (scleroderma) are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular and oral dryness may accompany primary or secondary Sj&ouml;gren's syndrome. Issues surrounding the management of this condition in the patient undergoing surgery include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       Pilocarpine",
"      </a>",
"      should not be given in the perioperative period to avoid the risk of bronchospasm, bradycardia, involuntary urination, vomiting, hypotension, and tremor; such manifestations may be confused with postoperative complications.",
"     </li>",
"     <li>",
"      Lubricating gel and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      are recommended during and after anesthesia to prevent corneal drying and abrasion.",
"     </li>",
"     <li>",
"      To prevent exacerbating ocular and oral dryness, the use of anticholinergic medications should be minimized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA who undergo total hip or knee replacement are at increased risk of prosthetic joint infection, which is further increased in the setting of revision arthroplasty and a previous prosthetic joint infection. These findings highlight the importance of perioperative prophylactic measures and vigilance during the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As previously mentioned, some patients with RA have an increased risk of surgical complications, such as atlantoaxial subluxation and neurologic damage. Lateral cervical radiographs with flexion and extension views should be obtained within the year prior to surgery.",
"     </li>",
"     <li>",
"      Risk factors associated with",
"      <span class=\"nowrap\">",
"       C1/C2",
"      </span>",
"      instability include glucocorticoid use, seropositivity, nodular disease, and erosive peripheral joint disease. A soft collar will not stabilize the cervical spine, but it usually reminds the staff to be gentle, particularly when the patient is sedated or unconscious. Preoperative radiographic evaluation that includes flexion and extension views of the cervical spine may detect significant subluxation in the absence of symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cricoarytenoid joint disease may cause difficulty with intubation. The physical symptoms of cricoarytenoid arthritis are dyspnea, hoarseness, dysphagia, odynophagia, sense of fullness in the throat, pain with speech, and radiation of pain to the ears. Investigation may be necessary with indirect laryngoscopy.",
"     </li>",
"     <li>",
"      If multiple joints require replacement, careful timing is necessary to allow optimal rehabilitation. As an example, upper extremity stabilization may be necessary to enable crutch ambulation prior to lower extremity surgery.",
"     </li>",
"     <li>",
"      Anemia is common in patients with RA. Postoperative blood transfusions are often required for large joint replacements such as the shoulder, hip and knee. Autologous blood donation can be arranged, if desired and medically appropriate. Iron supplementation should begin before and continue during the blood donation. Patients with the anemia of chronic disease often respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      . However, given the current safety of the blood supply, the cost-effectiveness of autologous blood donation (which is associated with risks), particularly if combined with erythropoietin therapy, is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"       \"Preoperative autologous blood donation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=see_link\">",
"       \"Total joint replacement for severe rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neutropenia also occurs in those with Felty's syndrome. Most commonly, such patients do well without any intervention; however, if neutrophil counts are extremely low and result in recurrent infection,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) can be administered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link\">",
"       \"Drug therapy in Felty's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extra-articular disease may also affect surgery (eg, lung fibrosis) and should be fully evaluated and treated, if possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Juvenile idiopathic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since children are skeletally immature, growth disturbances can occur after operation among those with juvenile idiopathic arthritis (JIA).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Joint replacement arthroplasty is usually delayed until patients are skeletally mature.",
"     </li>",
"     <li>",
"      Because life expectancy of young patients is greater than that of the current prostheses, surgeons may recommend osteotomy as an alternative procedure to joint replacement for those who have a stable joint with a useful functional range of movement, good muscle strength, and some remaining articular cartilage.",
"     </li>",
"     <li>",
"      Patients with JIA present significant anesthetic risks. Cervical spine involvement and micrognathia associated with temporomandibular joint involvement can make endotracheal intubation difficult. In a study to describe the long-term outcome and survival of hip replacement in a group of adult patients with JIA, survival of the prosthesis was significantly poorer in patients who had been taking long-term glucocorticoids and significantly better in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/34\">",
"       34",
"      </a>",
"      ]. However, the precise relationship between the survival of the prosthesis and treatment is uncertain. The indications for glucocorticoids, rather than treatment itself, may also have had an impact on the durability of prosthetic joints, as the study was not controlled for disease activity or severity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ankylosing spondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems related to spinal and costovertebral ankylosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A substantial risk of operative and perioperative complications if spinal involvement is more than minimal.",
"     </li>",
"     <li>",
"      Extensive ligamentous calcification and heterotopic ossification will make regional anaesthesia difficult.",
"     </li>",
"     <li>",
"      Endotracheal intubation may be impeded among those with severe kyphotic deformities of the cervical spine.",
"     </li>",
"     <li>",
"      Restricted chest excursion may further complicate intraoperative and postoperative care due to the increased risk of infection.",
"     </li>",
"     <li>",
"      Postoperative heterotopic ossification may limit total hip arthroplasty success [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link&amp;anchor=H41#H41\">",
"       \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Surgery'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link&amp;anchor=H38#H38\">",
"       \"Complications of total hip arthroplasty\", section on 'Heterotopic ossification'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psoriatic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues in psoriatic arthritis are principally related to skin disease or associated spondylitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a risk of flare of psoriatic skin disease at the operative site (Koebner's phenomenon).",
"     </li>",
"     <li>",
"      Stress of surgery may increase the risk of a generalized flare of psoriasis.",
"     </li>",
"     <li>",
"      An increased risk of post-operative infection has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hemophiliac arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor replacement needs to be monitored carefully and major elective surgery generally contraindicated for the subgroup of patients with high levels of factor antibody. HIV-infected patients have a higher rate of infection with retained metal ware.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since many patients with systemic lupus erythematosus (SLE) have multisystem disease, an increased risk of postoperative complications, such as wound infection, renal insufficiency, and pulmonary embolus, may be observed. In addition, hip arthroplasty in patients with SLE is associated with a higher risk of postoperative mortality compared with the general population or patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/35/15929/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with systemic lupus erythematosus may also have platelet counts of less than",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    In the author&rsquo;s experience, among such patients who require emergent surgery, intravenous immune globulin (IVIG) is very effective and may be preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . IVIG should be given if there is active disease with incipient vital organ failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Progressive systemic sclerosis (scleroderma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential problems among the patient with scleroderma undergoing surgery include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There may be a prolonged response to local anesthetic agents.",
"     </li>",
"     <li>",
"      Endotracheal intubation can be difficult due to decreased mouth aperture.",
"     </li>",
"     <li>",
"      Arterial vasospasm of different vascular beds, such as the coronary, renal, and intestinal arteries, may be observed.",
"     </li>",
"     <li>",
"      Skin scleroderma can reduce the availability of intravenous access.",
"     </li>",
"     <li>",
"      Since lung involvement is associated with increased postoperative mortality, preoperative assessment should include pulmonary function tests and preoperative arterial blood gases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link\">",
"       \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with symptoms and findings suggestive of pulmonary hypertension, preoperative echocardiography may allow estimation of pulmonary arterial pressure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure, conduction block, and arrhythmias, all resulting from fibrosis, and myocardial ischemia, due to non-epicardial coronary artery disease, may be observed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Cardiac disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scleroderma renal disease may cause hypertension or renal crisis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"       \"Scleroderma renal crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is an increased risk of aspiration due to esophageal dysmotility and gastroesophageal sphincter incompetence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"       \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25851827\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We perform a thorough preoperative evaluation, including a careful history and physical examination, with targeted laboratory studies and imaging procedures depending upon the underlying medical conditions or planned surgery. As examples, patients with rheumatoid arthritis should be evaluated for cervical spine involvement and cardiovascular disease, and patients undergoing elective joint replacement surgery should receive special attention to potential sources of infection. Testing usually performed in all patients includes a urinalysis, serum electrolyte levels, and serum concentrations of glucose, blood urea nitrogen, and creatinine, as well as a complete blood count and coagulation profile. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preoperative evaluation and management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'History and physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimizing the patient's medical condition preoperatively through physiotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight reduction may help prevent postoperative problems, particularly for patients undergoing surgery on their joints. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'General management issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged use of glucocorticoids may suppress the normal increase in endogenous cortisol that occurs in response to the stress of surgery. Supplementation of glucocorticoids may, therefore, be needed to mimic the body's own response to stress. Patients receiving 5 mg per day or less of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent preoperatively need only receive their usual doses of medication, or an equivalent dose (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      25 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      5 mg intravenously). Those undergoing minor surgical or dental procedures, endoscopic studies, or similar minimally stressful interventions may also be managed with low doses of supplemental glucocorticoids. For moderately stressful procedures or postoperative illnesses, such as pneumonia, higher doses of parenteral glucocorticoids are needed (eg, 100 mg of hydrocortisone is given intravenously every eight hours perioperatively and the dose is slowly reduced [but not the frequency] until the patient can be switched to his or her regular doses of oral medications). Alternatively, continuously dosed regimens may be used. (See",
"      <a class=\"local\" href=\"#H6802267\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs should be stopped at least three half-lives prior to surgery.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      , which permanently inhibits platelet cyclooxygenase, is discontinued at least one week prior to surgery to allow production of new platelets. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not advise stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      prior to surgery; discontinuation of MTX may result in a flare of disease activity in patients with RA, which may adversely affect rehabilitation. However, we do discontinue other agents that can cause leukopenia (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ) a few days preoperatively. We also withhold",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      for two weeks prior to elective surgery and resume treatment three days following, or whenever the patient is able to take oral medications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Methotrexate and other nonbiologic DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We withhold biologic DMARDs prior to surgery, usually for a period equivalent to one or two treatment cycles, and resume postoperatively when wound healing is complete. The duration for which the medication is withheld depends upon the individual agent. Biologic DMARDs should be stopped in the event of a serious infection. They should not be resumed until the infection is eradicated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Biological agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attention should be given to the approaches needed to address the particular disease-related risks associated with the following disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sj&ouml;gren's syndrome (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Sj&ouml;gren's syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Rheumatoid arthritis (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Rheumatoid arthritis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Juvenile idiopathic arthritis (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Juvenile idiopathic arthritis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ankylosing spondylitis (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Ankylosing spondylitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Psoriatic arthritis (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Psoriatic arthritis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemophiliac arthropathy (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Hemophiliac arthropathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Systemic lupus erythematosus'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Systemic sclerosis (scleroderma) (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Progressive systemic sclerosis (scleroderma)'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Axford JS, O'Callaghan C. Medicine, Second Edition, Blackwell Science, Cambridge 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/2\">",
"      Kelley JT, Conn DL. Perioperative management of the rheumatic disease patient. Bull Rheum Dis 2002; 51.",
"     </a>",
"    </li>",
"    <li>",
"     Figgie MP. Introduction to the surgical treatment of rheumatic diseases. In: Rheumatology, Klippel JH, Dieppe PA (Eds), Mosby, St. Louis 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/4\">",
"      Meune C, Touz&eacute; E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009; 48:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/5\">",
"      Vieira EM, Goodman S, Tanaka PP. [Anesthesia and rheumatoid arthritis]. Rev Bras Anestesiol 2011; 61:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/6\">",
"      Kwek TK, Lew TW, Thoo FL. The role of preoperative cervical spine X-rays in rheumatoid arthritis. Anaesth Intensive Care 1998; 26:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/7\">",
"      Mulroy WF, Estok DM, Harris WH. Total hip arthroplasty with use of so-called second-generation cementing techniques. A fifteen-year-average follow-up study. J Bone Joint Surg Am 1995; 77:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/8\">",
"      Nawabi DH, Chin KF, Keen RW, Haddad FS. Vitamin D deficiency in patients with osteoarthritis undergoing total hip replacement: a cause for concern? J Bone Joint Surg Br 2010; 92:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/9\">",
"      Holstege MS, Lindeboom R, Lucas C. Preoperative quadriceps strength as a predictor for short-term functional outcome after total hip replacement. Arch Phys Med Rehabil 2011; 92:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/10\">",
"      Wymenga AB, van Horn JR, Theeuwes A, et al. Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand 1992; 63:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/11\">",
"      Lehman DE, Capello WN, Feinberg JR. Total hip arthroplasty without cement in obese patients. A minimum two-year clinical and radiographic follow-up study. J Bone Joint Surg Am 1994; 76:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/12\">",
"      Pedersen AB, Sorensen HT, Mehnert F, et al. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am 2010; 92:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/13\">",
"      Eijsbouts A, van den Hoogen F, Laan R, et al. Similar response of adrenocorticotrophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1998; 37:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/14\">",
"      Friedman RJ, Schiff CF, Bromberg JS. Use of supplemental steroids in patients having orthopaedic operations. J Bone Joint Surg Am 1995; 77:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/15\">",
"      Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/16\">",
"      Liu SS, Bae JJ, Bieltz M, et al. Association of perioperative use of nonsteroidal anti-inflammatory drugs with postoperative myocardial infarction after total joint replacement. Reg Anesth Pain Med 2012; 37:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/17\">",
"      Jain A, Maini R, Nanchahal J. Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data. Ann Rheum Dis 2004; 63:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/18\">",
"      Pieringer H, Stuby U, Biesenbach G. The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008; 27:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/19\">",
"      Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/20\">",
"      Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/21\">",
"      Mushtaq S, Goodman SM, Scanzello CR. Perioperative management of biologic agents used in treatment of rheumatoid arthritis. Am J Ther 2011; 18:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/22\">",
"      Alvarez B, Arcos J, Fern&aacute;ndez-Guerrero ML. Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents. Curr Opin Pulm Med 2011; 17:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/23\">",
"      Schreiber S, Campieri M, Colombel JF, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 2001; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/24\">",
"      Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004; 25:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/25\">",
"      Talwalkar SC, Grennan DM, Gray J, et al. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005; 64:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/26\">",
"      Wendling D, Balblanc JC, Brousse A, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005; 64:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/27\">",
"      den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/28\">",
"      Giles JT, Gelber AC, Nanda S, et al. TNF inhibitor therapy increases the risk of post operative orthopedic infection in patients with rheumatoid arthritis (abstract). Arthritis Rheum 2004; 50:S660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/29\">",
"      Momohara S, Kawakami K, Iwamoto T, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/30\">",
"      Pham T, Bachelez H, Berthelot JM, et al. Abatacept therapy and safety management. Joint Bone Spine 2012; 79 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/31\">",
"      Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/32\">",
"      Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions... J Rheumatol 2007; 34:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/33\">",
"      Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/34\">",
"      Malviya A, Walker LC, Avery P, et al. The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate. J Bone Joint Surg Br 2011; 93:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/35\">",
"      Sundaram NA, Murphy JC. Heterotopic bone formation following total hip arthroplasty in ankylosing spondylitis. Clin Orthop Relat Res 1986; :223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/36\">",
"      Menon TJ, Wroblewski BM. Charnley low-friction arthroplasty in patients with psoriasis. Clin Orthop Relat Res 1983; :127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/35/15929/abstract/37\">",
"      Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol 2010; 37:1467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1826 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15929=[""].join("\n");
var outline_f15_35_15929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25851827\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENERAL MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medication management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6802267\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Methotrexate and other nonbiologic DMARDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Biological agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISEASE SPECIFIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ankylosing spondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hemophiliac arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Progressive systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25851827\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_35_15930="Examples of well differentiated NETs of the digestive organs";
var content_f15_35_15930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Examples of well differentiated neuroendocrine tumors of the digestive organs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) EC (enterochromaffin) cell NET (carcinoid) of the terminal ileum shows solid tumor nest with peritumoral fibrosis.",
"    <br>",
"     (B) Pancreatic NET with ribbon-like pattern and wide tumor-free spaces in between.",
"     <br>",
"      (C) Pancreatic insulinoma shows abundant amyloid deposition.",
"      <br>",
"       (D) Periampullary somatostatinoma shows tubuloglandular pattern with numerous psamomma bodies. (H&amp;E, 400x original magnification).",
"       <div class=\"footnotes\">",
"        NET: neuroendocrine tumor; H&amp;E: hematoxylin and eosin-stained.",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15930=[""].join("\n");
var outline_f15_35_15930=null;
var title_f15_35_15931="Types of IUI catheters";
var content_f15_35_15931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of catheters for intrauterine insemination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Design",
"      </td>",
"      <td class=\"subtitle1\">",
"       Structure",
"      </td>",
"      <td class=\"subtitle1\">",
"       Manufacturer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Double sheath",
"      </td>",
"      <td rowspan=\"2\">",
"       Soft, flexible outer sheath with memory and soft inner, double lumen catheter",
"      </td>",
"      <td>",
"       Wallace&reg;  insemination catheter (Smiths Medical)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cook&reg; Soft-Pass insemination catheter (Cook Women's Health, Spencer, IN, USA)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solid, thicker outer sheath with soft inner, double lumen catheter",
"      </td>",
"      <td>",
"       Gynetics&reg; insemination catheter (Gynetics Medical Products, Hamont-Achel, Belgium)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Single sheath",
"      </td>",
"      <td>",
"       Firm, flexible sheath catheter",
"      </td>",
"      <td>",
"       Tomcat&reg; insemination catheter (Kendall Sovereign, Mansfield, MA, USA)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Firm, semi-rigid catheter",
"      </td>",
"      <td>",
"       Makler&reg; IUI Cannula and insemination device (Sefi-Medical Instruments, Haifa, Israel)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Semi-rigid",
"      </td>",
"      <td>",
"       Cooper The Curve&reg;, Select IUI, Select MiniSpace (Cooper Surgical, Trumbull, CT, USA)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15931=[""].join("\n");
var outline_f15_35_15931=null;
var title_f15_35_15932="Causes of urticaria";
var content_f15_35_15932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identifiable causes of urticaria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Viral",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parasitic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       IgE-mediated allergic cases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Insects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Stinging (yellowjackets, bees, wasps, hornets, fire ants)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Biting (Triatoma [kissing bugs])",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Foods",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood products (urticarial transfusion reaction)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Latex (contact or inhaled)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact allergens (animal saliva, raw foods)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aeroallergens (rare)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Food additives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Direct mast cell activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Narcotics/opiates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle relaxants (eg, succinylcholine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiocontrast agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vancomycin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Physical stimuli",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dermatographism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Delayed pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cholinergic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vibratory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aquagenic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solar",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exertion/exercise",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Miscellaneous mechanisms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nonsteroidal antiinflammatory drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum sickness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transfusion reactions (distinct from IgE-mediated reactions)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hormone-associated (progesterone)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stinging nettle",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15932=[""].join("\n");
var outline_f15_35_15932=null;
var title_f15_35_15933="Congenital rubella ssx";
var content_f15_35_15933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency and clinical course of selected clinical findings following intrauterine rubella infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Manifestations in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Clinical manifestation",
"       </td>",
"       <td class=\"subtitle2\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle2\">",
"        Typical time of onset",
"       </td>",
"       <td class=\"subtitle2\">",
"        Course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hearing impairment",
"       </td>",
"       <td>",
"        60 percent",
"       </td>",
"       <td>",
"        Early infancy",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Heart defect",
"       </td>",
"       <td>",
"        45 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patent ductus arteriosus",
"       </td>",
"       <td class=\"sublist_other\">",
"        20 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        Early infancy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Peripheral pulmonic stenosis*",
"       </td>",
"       <td class=\"sublist_other\">",
"        12 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        Early infancy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microcephaly",
"       </td>",
"       <td>",
"        27 percent",
"       </td>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cataracts",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"       <td>",
"        Early infancy",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low birth weight (&lt;2500 g)",
"       </td>",
"       <td>",
"        23 percent",
"       </td>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        Poor weight gain may persist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatosplenomegaly",
"       </td>",
"       <td>",
"        19 percent",
"       </td>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        Transient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purpura",
"       </td>",
"       <td>",
"        17 percent",
"       </td>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        Transient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intellectual disability (mental retardation)",
"       </td>",
"       <td>",
"        13 percent",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningoencephalitis",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        Transient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiolucent bone lesions",
"       </td>",
"       <td>",
"        7 percent",
"       </td>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        Transient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinopathy",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        Early infancy",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Late-onset manifestations",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Hearing loss",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Intellectual disability",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Thyroid dysfunction",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Progressive panencephalitis",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes pulmonary arterial hypoplasia, supravalvular stenosis, valvular stenosis, and peripheral branch stenosis.",
"     <br>",
"      &bull; The frequency of these manifestations is not known, given the difficulty of establishing a diagnosis of congenital rubella infection in individuals older than one year of age.",
"      <br>",
"       &Delta; Includes hyperthyroidism, hypothyroidism, and thyroiditis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.",
"      <br>",
"       2. Banatvala JE, Brown DW. Rubella. Lancet 2004; 363:1127.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15933=[""].join("\n");
var outline_f15_35_15933=null;
var title_f15_35_15934="Inhaled GC doses for adults";
var content_f15_35_15934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated comparative daily doses for inhaled glucocorticoids in adolescents and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medium dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        High dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Beclomethasone HFA",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        80 to 240 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        240 to 480 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;480 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        40 mcg/dose",
"       </td>",
"       <td>",
"        (2 to 6 puffs)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        80 mcg/dose",
"       </td>",
"       <td>",
"        (1 to 3 puffs)",
"       </td>",
"       <td>",
"        (3 to 6 puffs)",
"       </td>",
"       <td>",
"        (&gt;6 puffs)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Budesonide DPI (Flexhaler)",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        180 to 600 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        600 to 1200 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;1200 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        90 mcg/dose",
"       </td>",
"       <td>",
"        (2 to 6 inhalations)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        180 mcg/dose",
"       </td>",
"       <td>",
"        (1 to 3 inhalations)",
"       </td>",
"       <td>",
"        (4 to 6 inhalations)",
"       </td>",
"       <td>",
"        (&gt;6 inhalations)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Budesonide DPI (Turbuhaler)",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"sublist1_start\">",
"        200 to 600 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        600 to 1200 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;1200 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 mcg/dose",
"       </td>",
"       <td>",
"        (2 to 6 inhalations)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        200 mcg/dose",
"       </td>",
"       <td>",
"        (1 to 3 inhalations)",
"       </td>",
"       <td>",
"        (3 to 6 inhalations)",
"       </td>",
"       <td>",
"        (&gt;6 inhalations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        400 mcg/dose",
"       </td>",
"       <td>",
"        (1 inhalation)",
"       </td>",
"       <td>",
"        (2 to 3 inhalations)",
"       </td>",
"       <td>",
"        (&gt;3 inhalations)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Ciclesonide HFA",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        80 to 320 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        320 to 640 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;640 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        80 mcg/puff",
"       </td>",
"       <td>",
"        (1 to 4 puffs)",
"       </td>",
"       <td>",
"        (4 to 8 puffs)",
"       </td>",
"       <td>",
"        (&gt;8 puffs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        160 mcg/puff",
"       </td>",
"       <td>",
"        (1 to 2 puffs)",
"       </td>",
"       <td>",
"        (2 to 4 puffs)",
"       </td>",
"       <td>",
"        (&gt;4 puffs)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Flunisolide HFA",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"sublist1_start\">",
"        320 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        320 to 640 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;640 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        80 mcg/puff",
"       </td>",
"       <td>",
"        (4 puffs)",
"       </td>",
"       <td>",
"        (4 to 8 puffs)",
"       </td>",
"       <td>",
"        (&gt;8 puffs)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Fluticasone HFA",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        88 to 264 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        264 to 440 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;440 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        44 mcg/puff",
"       </td>",
"       <td>",
"        (2 to 6 puffs)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        110 mcg/puff",
"       </td>",
"       <td>",
"        (2 puffs)",
"       </td>",
"       <td>",
"        (3 to 4 puffs)",
"       </td>",
"       <td>",
"        (&gt;4 puffs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        220 mcg/puff",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        (&gt;2 puffs)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Fluticasone DPI",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        100 to 300 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        300 to 500 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;500 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50 mcg/dose",
"       </td>",
"       <td>",
"        (2 to 6 inhalations)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 mcg/dose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        (3 to 5 inhalations)",
"       </td>",
"       <td>",
"        (&gt;5 inhalations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        250 mcg/dose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        (&gt;2 inhalations)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Mometasone DPI",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        220 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        440 mcg",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &gt;440 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        110 mcg/dose",
"       </td>",
"       <td>",
"        (2 inhalations)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        220 mcg/dose",
"       </td>",
"       <td>",
"        (1 inhalation)",
"       </td>",
"       <td>",
"        (2 inhalations)",
"       </td>",
"       <td>",
"        (&gt;2 inhalations)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Notes:",
"    </strong>",
"    <br>",
"     <strong>",
"      The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy.",
"     </strong>",
"     The clinician must monitor the patient's response on several clinical parameters and adjust the dose accordingly. The stepwise approach to therapy emphasizes that once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects.",
"     <br>",
"      Some doses may be outside package labeling.",
"      <br>",
"       The conventions for expressing doses from metered dose inhalers (MDIs) and dry powder inhalers (DPIs) vary from one country to another. In the United States, MDI doses are expressed as the actuator dose (the amount of drug leaving the actuator and delivered to the patient, eg, fluticasone 44, 110 or 220 mcg per spray). This is different from the dose expressed as the valve dose (the amount of drug leaving the valve, not all of which is available to the patient), which is used in many European countries and in some of the scientific literature (eg, fluticasone 50, 125, or 250 mcg per spray). In the United States, DPI doses may be expressed as the amount of drug in the inhaler chamber following priming (eg, mometasone DPI 110 mcg or 220 mcg per dose). In other countries, DPI doses may be expressed as the amount of drug delivered from the mouthpiece (eg, mometasone DPI 100 mcg or 200 mcg per dose).",
"       <div class=\"footnotes\">",
"        HFA: hydrofluoroalkane propellant metered dose inhaler; CFC: chlorofluorocarbon propellant metered dose inhaler.",
"        <br/>",
"        * Not available in the United States.",
"       </div>",
"       <div class=\"reference\">",
"        Adapted from National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on December 6, 2012).",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15934=[""].join("\n");
var outline_f15_35_15934=null;
var title_f15_35_15935="Histo in AIDS";
var content_f15_35_15935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HIV patient with histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph shows diffuse fine nodular infiltrates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. John W Baddley.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_35_15935=[""].join("\n");
var outline_f15_35_15935=null;
